var title_f22_25_22928="Corneal foreign body";
var content_f22_25_22928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F87226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F87226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Corneal foreign body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corneal foreign body that has been present for several days, resulting in inflammatory reaction to iron in the foreign body and causing local haze and surface breakdown that picks up stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22928=[""].join("\n");
var outline_f22_25_22928=null;
var title_f22_25_22929="Meconium pseudocyst 2";
var content_f22_25_22929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meconium pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of the abdomen in a fetus at gestational age of 18 weeks with a meconium pseudocyst (arrow) and peritoneal calcifications (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22929=[""].join("\n");
var outline_f22_25_22929=null;
var title_f22_25_22930="Perforating folliculitis - hand";
var content_f22_25_22930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforating folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules with central hyperkeratosis were present on the extremities of this woman with perforating folliculitis and renal failure. Perforating folliculitis most often occurs in the setting of renal failure or diabetes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Patrick Keehan, D.O. and Greg Hosler, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22930=[""].join("\n");
var outline_f22_25_22930=null;
var title_f22_25_22931="Carpenter bee";
var content_f22_25_22931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carpenter bee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22931=[""].join("\n");
var outline_f22_25_22931=null;
var title_f22_25_22932="Breast cyst ultrasound - pear shaped";
var content_f22_25_22932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Breast cyst ultrasound - pear shaped",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ultrasound of a palpable mass in the right breast (A) shows a 3 cm pear shaped anechoic structure with back wall enhancement (red arrow), through transmission (green arrows), and no internal enhancement on the Doppler study (B), consistent with a benign simple cyst. The mammogram revealed a non specific soft tissue mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesty of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22932=[""].join("\n");
var outline_f22_25_22932=null;
var title_f22_25_22933="Zidovudine: Patient drug information";
var content_f22_25_22933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zidovudine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     see \"Zidovudine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/55/27512?source=see_link\">",
"     see \"Zidovudine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Retrovir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Zidovudine&reg;;",
"     </li>",
"     <li>",
"      AZT&trade;;",
"     </li>",
"     <li>",
"      Novo-AZT;",
"     </li>",
"     <li>",
"      Retrovir&reg;;",
"     </li>",
"     <li>",
"      Retrovir&reg; (AZT&trade;)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause unsafe changes in blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700737",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause muscle aches and stiffness if it is used for long periods of time. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zidovudine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11909 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22933=[""].join("\n");
var outline_f22_25_22933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235151\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235152\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028562\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028564\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028563\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028568\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028569\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028571\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028566\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028567\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028572\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028573\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=related_link\">",
"      Zidovudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/55/27512?source=related_link\">",
"      Zidovudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_25_22934="Pneumococcal conjugate vaccine (13-valent): Pediatric drug information";
var content_f22_25_22934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pneumococcal conjugate vaccine (13-valent): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/56/39814?source=see_link\">",
"    see \"Pneumococcal conjugate vaccine (13-valent): Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9926715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prevnar 13&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11575096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prevnar 13&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10105915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated (Bacterial)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10105922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/56/39814?source=see_link\">",
"      see \"Pneumococcal conjugate vaccine (13-valent): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     I.M.: 0.5 mL per dose;",
"     <b>",
"      Note:",
"     </b>",
"     Preterm infants should be vaccinated according to their chronological age from birth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Recommended schedule:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants (6 weeks and &le;6 months): 0.5 mL/dose for 4 total doses; the first dose may be given as young as 6 weeks of age, but is typically given at 8 weeks (2 months of age); the 3 remaining doses are usually given at 4, 6, and 12-15 months of age. The recommended dosing interval is 4-8 weeks. The minimum interval between doses in children &lt;1 year of age is 4 weeks. The minimum interval between the third and fourth dose is 8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 7-11 months (previously unvaccinated): 0.5 mL for 3 total doses; 2 doses at least 4 weeks apart, followed by a third dose at 12-15 months, separated from second dose by at least 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 12-23 months (previously unvaccinated): 0.5 mL for 2 total doses, at least 8 weeks apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 24-59 months: Healthy children: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 24-71 months with underlying medical conditions (previously unvaccinated): 0.5 mL for a total of 2 doses, separated by 8 weeks [CDC 59(RR-11), 2010]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents 6-17 years: 0.5 mL as a single dose. If PCV7 was previously administered, give PCV13 &ge;8 weeks after that dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Previously vaccinated with PCV7 and/or PCV13 with a lapse in administration (ACIP recommendations):",
"     </b>",
"     [CDC 59(RR-11), 2010]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 7-11 months and previously received 1 or 2 doses: 0.5 mL dose at 7-11 months of age, followed by a second dose &ge;8 weeks later at 12-15 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 12-23 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously received 1 dose at &lt;12 months of age: 0.5 mL dose, followed by a second dose &ge;8 weeks later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously received 1 dose at &ge;12 months of age: 0.5 mL dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously received 2 or 3 doses before age 12 months: 0.5 mL dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 24-59 months (healthy children with any incomplete schedule): 0.5 mL dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 24-71 months with an underlying medical condition:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously received &lt;3 doses: 0.5 mL dose &ge;8 weeks after the most recent dose, followed by a second dose &ge;8 weeks later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously received 3 doses: 0.5 mL as a single dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Previously completed vaccination series with PCV7 (4 doses) (ACIP recommendations):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 14-59 months: 0.5 mL as a single supplemental dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 24-71 months with an underlying medical condition: 0.5 mL as a single supplemental dose &ge;8 weeks after the most recent dose of PCV7 or PPSV23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      High risk for invasive pneumococcal disease (ACIP recommendations):",
"     </b>",
"     Children and Adolescents 6-18 years: 0.5 mL as a single dose &ge;8 weeks after the most recent dose of PCV7 or PPSV23 (if applicable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Immunization:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Efficacy of PCV13 administered &lt;5 years after PPSV23 is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults &ge;50 years: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults &ge;19 years with specified underlying medical conditions (CDC, 2012): Eligible adults should be vaccinated at their next pneumococcal vaccination opportunity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Pneumococcal vaccine na&iuml;ve:",
"     </i>",
"     (No previous PCV13 or PPSV23 vaccine): Administer PCV13 0.5 mL as a single dose followed by 1 dose of PPSV23 8 weeks later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Previously vaccinated with PPSV23:",
"     </i>",
"     PCV13 0.5 mL as a single dose &ge;1 year after the last dose of PPSV23",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10010079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevnar 13&reg;: 2 mcg of each capsular saccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4 mcg of serotype 6B [bound to diphtheria CRM",
"     <sub>",
"      197",
"     </sub>",
"     protein ~34 mcg] per 0.5 mL (0.5 mL) [contains aluminum, polysorbate 80, and yeast]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10010044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10105923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Shake vial well before withdrawing the dose; administer I.M. in either the anterolateral aspect of the thigh or arm;",
"     <b>",
"      not for I.V. or SubQ administration.",
"     </b>",
"     Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10105984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; discard if frozen.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10105916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunization against",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     infection caused by serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F (FDA approved in ages 6 weeks to 17 years and adults &ge;50 years). Prevention of otitis media in infants and children caused by",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F  (FDA approved in ages 6 weeks to 5 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following [CDC 59(RR-11), 2010]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; All infants and children age 2-59 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Children 60-71 months with underlying medical conditions including:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &minus; Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &minus; Children with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &minus; Children with immunocompromising conditions, including congenital immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Children who received &ge;1 dose of 7-valent pneumococcal vaccine (PCV7)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Children and Adolescents 6-18 years at increased risk for invasive pneumococcal disease due to anatomic or functional asplenia (including sickle cell disease), HIV infection or other immunocompromising conditions, cochlear implant, or cerebrospinal fluid leaks (regardless of prior receipt of PCV7 or PPSV23). Routine use is not recommended for healthy children &ge;5 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The ACIP also recommends routine vaccination for adults &ge;19 years with the following immunocompromising conditions (CDC, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Immunocompetent persons with cerebrospinal fluid leaks or cochlear implants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Persons with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, or congenital or acquired asplenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Persons with immunocompromising conditions including congenital or acquired immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10010021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13&reg;) may be confused with Pneumococcal 7-Valent Conjugate Vaccine (Prevnar&reg;) or with Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumovax&reg; 23)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F10010063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Central nervous system: Chills, drowsiness, fatigue, fever, headache, insomnia, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: HIves, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Appetite decreased, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Erythema, limitation of arm motion, pain, swelling, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Abnormal crying, erythema multiforme,  febrile seizures, hypersensitivity reaction (bronchospasm, dyspnea, facial edema), seizure, urticaria, urticaria-like rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse reactions observed with PCV7 which may also be seen with PCV-13: Anaphylactic reaction, angioneurotic edema, apnea, breath holding, edema, hypotonic hyporesponsive episode, injection site reaction (dermatitis, pruritus), lymphadenopathy (localized), shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10105918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pneumococcal vaccine or any component, including diphtheria toxoid",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10105944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo-/radiation therapy or other immunosuppressive therapy including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with asplenia, HIV infection, sickle-cell disease, or other  chronic illnesses [CDC 59(RR-11), 2010]. Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Febrile seizures have been reported; CDC reports indicate that young children appear to be at increased risk of febrile seizures when given the pneumococcal conjugate vaccine (PCV13) at the same time as the inactivated influenza virus vaccine (TIV); the risk appears to be greatest from ages 12-23 months. Because febrile seizures are typically benign and occur in 2% to 5% of all young children, the ACIP does not recommend a delay in administration of either vaccine or altering the vaccine schedule in any manner due to the potential risk of infection. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009). Concurrent administration of PCV13 and PPV23 has not been studied and is not recommended (CDC, 2010). Not to be used to treat pneumococcal infections or to provide immunity against diphtheria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10105919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine administration. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Apnea has occurred following intramuscular vaccine administration in premature neonates; consider clinical status implications. Contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10073253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Inactivated): Pneumococcal Conjugate Vaccine (13-Valent) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent).  Management: Immune response to these vaccines may be diminished when given concomitantly to patients 65 years old or older.  When practical, consider separating doses of these vaccines by 1 month or more for these patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10010056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10010057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not shown adverse fetal effects. Inactivated vaccines have not been shown to cause increased risks to the fetus (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10105986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10105921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains saccharides of capsular antigens of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually conjugated to CRM197 protein",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10105987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This vaccine is used to prevent bacterial meningitis and ear infections. This vaccine will help prevent the disease and stop its spread from person to person. It may be given with other childhood vaccines. If moderately to severely ill, delay vaccination until recovered. This vaccine may be given during a minor illness, such as a cold. Side effects from this vaccine include redness, tenderness, or swelling at the injection site and mild fever. Contact  healthcare provider immediately for high fever, seizures, unusual behavior, or signs of allergic reaction (respiratory difficulty, hoarseness or wheezing, hives, paleness, weakness, fast heartbeat, dizziness, or swelling of the throat).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10105924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Pneumococcal 13-valent conjugate vaccine (PCV13; Prevnar 13&reg;) is the successor to the previously-marketed pneumococcal 7-valent conjugate vaccine (PCV7; Prevnar&reg;). Prevnar 13&reg; contains an additional six serotypes of",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     , compared to the seven serotypes provided in the original Prevnar&reg; formulation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, \"Recommendations for the Prevention of",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(1):186-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/20498180/pubmed\" id=\"20498180\" target=\"_blank\">",
"        20498180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-61.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-11):1-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/21150868/pubmed\" id=\"21150868\" target=\"_blank\">",
"        21150868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:816-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/23051612/pubmed\" id=\"23051612\" target=\"_blank\">",
"        23051612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reefhuis J, Honein MA, Whitney CG, et al, &ldquo;Risk of Bacterial Meningitis in Children With Cochlear Implants,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(5):435-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/25/22934/abstract-text/12890842/pubmed\" id=\"12890842\" target=\"_blank\">",
"        12890842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15567 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22934=[""].join("\n");
var outline_f22_25_22934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9926715\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11575096\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105915\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105922\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010079\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010044\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105923\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105984\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105916\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010021\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010063\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105918\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105944\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105919\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299890\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073253\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010056\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010057\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105986\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105921\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105987\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105924\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/56/39814?source=related_link\">",
"      Pneumococcal conjugate vaccine (13-valent): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_25_22935="Whales tail EUS";
var content_f22_25_22935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Celiac artery bifurcation seen on endoscopic ultrasound (whale's tail sign)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top: Radial EUS image showing the celiac artery (CA) bifurcating into the hepatic artery (HA) and the splenic artery (SA), or the so-called \"whale's tail\" sign. Bottom: Simplification of top image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22935=[""].join("\n");
var outline_f22_25_22935=null;
var title_f22_25_22936="Seasonal affective disorder";
var content_f22_25_22936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seasonal affective disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22936/contributors\">",
"     Sy Atezaz Saeed, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22936/contributors\">",
"     Timothy J Bruce, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22936/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22936/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/25/22936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive episodes are a primary public health problem and one of the most common psychiatric conditions seen in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 10 to 40 percent of patients in the primary care setting have significant depressive symptoms, although less than one-half meet the criteria for major depressive disorder as defined by DSM-IV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/2\">",
"     2",
"    </a>",
"    ]. Some of these depressive episodes tend to follow regular seasonal patterns, occurring reliably at particular times of year. These seasonal mood patterns have been termed Seasonal Affective Disorder (SAD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAD, or the seasonal pattern of major depressive episodes, is most simply defined as recurring depression with seasonal onset and remission. It is not considered a separate mood disorder. The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) describes it as a \"specifier\" or a subtype that can occur within any of the following major mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major Depressive Disorder, recurrent (characterized by recurring major depressive episodes)",
"     </li>",
"     <li>",
"      Bipolar I Disorder (characterized by a manic or mixed episode(s) with or without a major depressive episode(s))",
"     </li>",
"     <li>",
"      Bipolar II Disorder (characterized by a hypomanic episode(s) with a major depressive episode(s))",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two seasonal patterns of SAD have been described: the fall-onset SAD and the summer-onset SAD. The fall-onset type, also known as \"winter depression,\" is most recognized. In this subtype, major depressive episodes begin in late fall to early winter and remit during summer months. Although less documented in the literature, a spring-onset pattern has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seasonal variations in mood have been documented by both retrospective and prospective studies. In a review of these studies, the prevalence estimates of SAD across 20 retrospective studies ranged from 0 to 9.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/5\">",
"     5",
"    </a>",
"    ]. SAD was more prevalent at higher northern latitudes, although the net effect of latitude is probably small [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/6\">",
"     6",
"    </a>",
"    ]. People who migrate to higher latitudes may be more susceptible to developing SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A milder form of SAD, termed subsyndromal SAD or S-SAD, has also been reported and may be more prevalent than SAD. In one telephone survey, 4 to 6 percent of those surveyed experienced fall-onset SAD, and another 10 to 20 percent had subsyndromal features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly all clinical studies report a higher incidence of winter SAD in women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, the true sex ratio may be distorted by selection bias. One study that employed fairly strict criteria for diagnosis found that SAD with major depressive episodes was more common in men, while women more commonly experienced seasonal minor depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the prevalence of SAD in different age groups are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/9\">",
"     9",
"    </a>",
"    ]. Some data suggest that the average age of onset of SAD is approximately 23 years and that risk decreases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/3\">",
"     3",
"    </a>",
"    ]. Cases of childhood SAD have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence studies of SAD and nonseasonal mood disorders among relatives of SAD sufferers and in twin studies suggest a familial contribution to its development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, it is not known whether SAD is a heritable disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of SAD is not well understood. It is believed that the decreasing daylight available in fall and winter triggers a depressive episode in people predisposed to develop the disorder. However, no studies have established a causal relationship between decreasing daylight and the development of winter SAD.",
"   </p>",
"   <p>",
"    A number of pathogenetic mechanisms have been proposed, including abnormal melatonin metabolism and altered circadian rhythm, although studies in support of these hypotheses have been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis that appears to have most support involves the neurotransmitter serotonin. Evidence supporting this hypothesis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies have found a decrease of central serotonergic activity in patients with SAD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/16-19\">",
"       16-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serotonin appears to play an important role in the mechanism of action of light therapy, as the benefits of light therapy have been found to be reduced by tryptophan depletion [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of patients with SAD who were in remission during the summer found that patients who received an amino acid beverage that did not contain tryptophan experienced rapid lowering of brain serotonin associated with onset of depressive symptoms, while patients who received a beverage with tryptophan had no alteration in brain serotonin and had no symptom recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variation in levels of serotonin transporter binding protein with season and duration of daily sunshine were found in healthy adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/23\">",
"       23",
"      </a>",
"      ]. Higher levels of the transport protein were found in the fall and winter, and associated with lower synaptic serotonin levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYNDROMAL VALIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While knowledge of SAD and its treatment continues to grow, the debate over its syndromal validity continues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/24\">",
"     24",
"    </a>",
"    ]. Some have argued that winter depression is a temporal coincidence among some people with recurrent mood disorder. Others have suggested that the seasonal variations in mood and behavior noted in the general population also speak against the distinctiveness of SAD as a diagnostic entity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, SAD symptoms overlap with other more established subtypes of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]: Spring-onset SAD with typical depressive episodes and fall-onset SAD with atypical depression. There are also reports that fall-onset SAD responds to treatment with MAOIs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/28\">",
"     28",
"    </a>",
"    ], the treatment of choice for atypical depression. Although less studied, spring-onset SAD appears to respond to the same antidepressant pharmacotherapy used effectively to treat non-seasonal depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other investigators have argued that the syndromal validity of SAD is supported by reports that the ratio of fall-onset SAD to spring-onset SAD increases with increasing latitude and that fall-onset SAD, in particular, tends to be longer and more severe at higher latitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, fall-onset SAD has responded to artificial bright light therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Nonseasonal atypical depression fails to respond to phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although further research will be needed to establish the syndromal validity and diagnostic distinctiveness of SAD, the usefulness of the concept is supported when considering the marked functional disability it can cause and its unique responsiveness to light therapy, thereby offering physicians an additional, effective treatment option for clearly established fall-onset SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fall-onset SAD is characterized by atypical symptoms of depression including [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased rather than decreased sleep",
"     </li>",
"     <li>",
"      Increased rather than decreased appetite with carbohydrate craving",
"     </li>",
"     <li>",
"      Marked increase in weight",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Interpersonal difficulties (especially rejection sensitivity)",
"     </li>",
"     <li>",
"      Leaden paralysis (heavy, leaden feelings in arms or legs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, spring-onset SAD is characterized by typical vegetative symptoms of depression such as weight loss, decreased sleep, and poor appetite. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although early studies suggested that most patients with fall-onset SAD also experienced hypomanic episodes in late spring to early summer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/34\">",
"     34",
"    </a>",
"    ], more recent studies report that most SADs occur as unipolar major depressive disorders. A substantial minority show Bipolar II patterns of the disorder (ie, have accompanying hypomanic episodes), and very few show a Bipolar I pattern (ie, are associated with a manic episode) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Table 1 summarizes the DSM-IV-TR diagnostic criteria for a major depressive episode (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ). Table 2 describes the diagnostic criteria for the \"seasonal pattern specifier\" (",
"    <a class=\"graphic graphic_table graphicRef55628 \" href=\"UTD.htm?3/21/3419\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light therapy is uniquely effective for fall-onset SAD, although all available treatment options should be considered when planning treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Light therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Agency for Healthcare Research and Quality (AHRQ) has published practice guidelines for depression in primary care that include treatment of seasonal depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/32\">",
"     32",
"    </a>",
"    ]. These guidelines recommend that light therapy be considered for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-psychotic well-documented seasonal depression",
"     </li>",
"     <li>",
"      Winter depressive episodes occurring within recurrent major depressive disorder",
"     </li>",
"     <li>",
"      Winter depressive episodes occurring within bipolar II disorder",
"     </li>",
"     <li>",
"      Milder seasonal depressive episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also advise that the decision to use light therapy, as well as its administration, involve a professional experienced and trained in its use.",
"   </p>",
"   <p>",
"    Circumstances in which light therapy is considered a first-line treatment include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient is not severely suicidal",
"     </li>",
"     <li>",
"      There are medical reasons to avoid antidepressants",
"     </li>",
"     <li>",
"      There is a history of a favorable response to light therapy",
"     </li>",
"     <li>",
"      There is no history of a significant negative response to light therapy",
"     </li>",
"     <li>",
"      The patient requests it (with the above four criteria met)",
"     </li>",
"     <li>",
"      An experienced practitioner deems it indicated (with the first four criteria met)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Light therapy is also a second-line option for patients who fail to respond to an adequate trial of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature regarding the efficacy of light therapy in patients with SAD is limited by design problems, including small sample sizes, inadequate blinding and placebo groups, and inconsistencies in the timing and dose of therapy. The best data are from the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 158 patients with SAD used high and low-dose negative ion generators as comparison conditions and found that bright light therapy using a light box was superior to non-light control conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study of 96 patients with SAD used negative ion boxes as sham light generators for the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/37\">",
"       37",
"      </a>",
"      ]. Light therapy had a significant effect compared with placebo after three weeks of treatment; after four weeks, 61 percent had responded to morning light, 50 percent to evening light, and only 32 percent to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of randomized trials found that bright light and dawn simulation therapies were associated with a significant reduction in depression symptom severity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the long-term efficacy of light therapy has not been established and the prophylactic use of light therapy in patients with a history of SAD also has not been studied.",
"   </p>",
"   <p>",
"    Based on our clinical experience, we consider prophylactically initiating light therapy at the start of the season in which patients have experienced symptoms in the past, particularly when there is a history of two or more prior severe episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light therapy involves exposure to visible light that produces a minimum of 2500 lux at eye level. Early studies used a two-hour session of 2500-lux exposure, but subsequent studies have found that 10,000-lux for 30 minutes per day is equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/36,39\">",
"     36,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that have predicted a positive response to light therapy include a history of hypersomnia, a preponderance of atypical vegetative symptoms, an increased intake of sweet foods in the afternoon, and a history of reactivity to ambient light [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Light therapy is initiated with a 10,000-lux box. The patient's eyes should remain open throughout the treatment session. Staring directly into the light source, however, is not advised. Treatment is started with one, 10 to 15 minute session per day, gradually increasing the session's duration to 30 to 45 minutes, depending upon response. Sessions should be increased to twice a day, if symptoms remain unresolved or worsen. Although there is no apparent reason for limiting the duration of sessions if the side effects are not severe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/43\">",
"     43",
"    </a>",
"    ], ninety minutes a day remains the conventional daily maximum duration of therapy.",
"   </p>",
"   <p>",
"    To reduce risks associated with poor quality construction, commercially available fixtures are recommended over homemade devices. Fluorescent light is preferred over incandescent, primarily because the small point source of the latter is more conducive to retinal damage. In addition, patients are advised to seek fixtures with features designed to protect the eyes such as light dispersion and screens that eliminate UV rays. Contrary to initial belief, \"full-spectrum\" light is unnecessary. Intensity, not spectrum, appears to be the critical factor in attaining an antidepressant effect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal time of day for light therapy has not been established. Some studies have reported that morning sessions produced better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/36,44\">",
"     36,44",
"    </a>",
"    ], while others have failed to show any significant difference between times of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Convenience should dictate the decision since there are no clear indications supported by controlled data.",
"   </p>",
"   <p>",
"    Some patients have an immediate response to light therapy, though typically it takes two to four days before a sustained antidepressant response is evident. Some studies have found that it can take several weeks for a response to light therapy to appear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/47\">",
"     47",
"    </a>",
"    ]; thus, a lack of response within the first week should not be taken as a treatment failure. The treatment plan should, however, be reevaluated if there is any clinical worsening or if a response is not evident by four to six weeks.",
"   </p>",
"   <p>",
"    Premature discontinuation of light therapy can precipitate relapse. Responders to light therapy should continue this treatment until sufficient daily light exposure is available to them through other sources, typically from springtime sun [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Light boxes can be obtained through a variety of manufacturers online, with prices ranging from $200 to more than $500 depending upon features. A partial list of sources for light boxes is found in the attached table (",
"    <a class=\"graphic graphic_table graphicRef65208 \" href=\"UTD.htm?23/5/23645\">",
"     table 3",
"    </a>",
"    ). Light therapy is not universally covered by health insurance in the United States.",
"   </p>",
"   <p>",
"    Useful adjuncts to light therapy include taking daily walks outside, enhancing indoor lighting with regular lamps and fixtures, setting a timer on a light to go on early in the morning in the patient's bedroom, and using a dawn simulator for a more naturalistic artificial dawn [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/39\">",
"     39",
"    </a>",
"    ]. There is no evidence that tanning salons, where the eyes are generally covered and the subject's skin is exposed to light, are useful for SAD. In addition, the light sources in tanning salons are relatively high in UV rays, which can be harmful to both the eyes and the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;When properly administered, light therapy appears to have few side effects, which are typically reversible. Reported side effects include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/35,48\">",
"     35,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Photophobia",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Hypomania",
"     </li>",
"     <li>",
"      Insomnia (if therapy is administered too late in the day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retinal damage is a theoretical adverse effect; it has not been reported to date.",
"   </p>",
"   <p>",
"    Side effects are likely to respond to a \"dose\" reduction that can be accomplished by decreasing the duration of sessions, increasing the distance from the light source, or taking periodic breaks during sessions. Caution is needed when using light therapy in patients who have photosensitive skin, medical conditions that render their eyes vulnerable to phototoxicity, or a tendency toward mania [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies, none of which specifically excluded seasonal variations, have demonstrated the efficacy of pharmacotherapy for mood disorders. These studies support the use of conventional first-line pharmacotherapy for the treatment of SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a few randomized trials have specifically investigated the use of antidepressants in patients with fall-onset SAD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of two randomized trials (136 patients with seasonal affective disorder) compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      with light therapy and found that response was comparable, with approximately 66 percent of participants improved in both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, 68 outpatients with fall-onset SAD were randomly assigned to five weeks of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      20 mg per day or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/50\">",
"       50",
"      </a>",
"      ]. Both groups showed significant improvement. The fluoxetine group had lower depression scores at termination than the placebo group, but these differences did not achieve statistical significance. On the other hand, the rate of clinical response in the fluoxetine group was significantly greater than the placebo group (59 versus 34 percent).",
"     </li>",
"     <li>",
"      A second group randomly assigned 34 patients with fall-onset SAD to treatment with the monoamine oxidase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"       moclobemide",
"      </a>",
"      (400 mg per day) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/51\">",
"       51",
"      </a>",
"      ]. After three weeks there was no difference between the groups on scales measuring depression severity. However, on measures of atypical depressive symptoms, patients in the active treatment demonstrated significantly more improvement than the placebo group, as early as one week after starting therapy.",
"     </li>",
"     <li>",
"      In a study of 183 depressed patients, 51 of whom had SAD, six weeks of treatment with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"       moclobemide",
"      </a>",
"      (300 to 450 mg per day) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (20 to 40 mg per day) resulted in full remission in 52 percent of patients with SAD and in 37 percent of patients with other depressive disorder. Altogether, 79 and 70 percent of patients, respectively, had a significant benefit from the treatment.",
"     </li>",
"     <li>",
"      A Canadian study randomly assigned 96 patients with seasonal affective disorder to treatment with light therapy plus placebo pill or to sham light therapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/52\">",
"       52",
"      </a>",
"      ]. There was no difference between the groups in overall response (67 percent in both groups) or remission (50 percent for light and 54 percent for fluoxetine), although the light treatment group had earlier response and fewer side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Open-label studies have also suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    may be an effective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, a placebo-controlled study reported that D-fenfluramine, which stimulates release and inhibits reuptake of serotonin, alleviated both depressed mood and carbohydrate craving in patients with fall-onset SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since SAD can occur in both bipolar and unipolar disorders, the type of disorder should determine what medications should be selected. As with light therapy, clinicians should be sensitive to the risk of precipitating a manic episode in bipolar disorder patients when using antidepressants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, pharmacotherapy is indicated in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who have had a prior positive response to antidepressants or mood stabilizers",
"     </li>",
"     <li>",
"      Patients at high suicide risk",
"     </li>",
"     <li>",
"      Patients with significant functional impairment",
"     </li>",
"     <li>",
"      Patients with a history of moderate to severe recurrent depression",
"     </li>",
"     <li>",
"      Patients who prefer pharmacotherapy",
"     </li>",
"     <li>",
"      Patients who have failed light therapy or psychotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Seasonal versus continuous pharmacotherapy",
"    </span>",
"   </p>",
"   <p>",
"    There is limited evidence to address whether either preventive or continuous pharmacotherapy is indicated for patients with SAD. Most studies of pharmacotherapy for SAD have only been short-term (up to eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/55\">",
"     55",
"    </a>",
"    ]. Additionally, prospective studies indicate that only 50 to 70 percent of patients with SAD report recurrent episodes in subsequent seasons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, three large randomized trials have evaluated preventive therapy with initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or placebo in the fall and continued through the spring, in 1042 patients with a history of SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/59\">",
"     59",
"    </a>",
"    ]. Recurrence rates of depression were lower for patients treated with bupropion (13 to 19 percent versus 21 to 31 percent). Depression rates in spring and summer, after stopping active medication, were low and not different than for placebo.",
"   </p>",
"   <p>",
"    Given the uncertainty of recurrence, patients may be appropriately managed with symptomatic treatment only. The decision to use either preventive (initiated in fall and then discontinued) or continuous treatment should be individualized, considering severity of illness and patient motivation and preference. For patients who will receive preventive medication, treatment should be initiated at least four weeks prior to the expected onset of symptoms. The option to continue medication should be considered for individuals who have been symptomatic later in the season, or who require long taper periods (eg higher doses or significant discontinuation symptoms). Patients receiving continuous treatment should be monitored for signs of hypomania or mania if their risk for bipolar disorder has not been ruled-out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies demonstrate the effectiveness of electroconvulsive therapy (ECT) for treating major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of resistant depression in adults\", section on 'Electroconvulsive therapy'",
"    </a>",
"    .) While there are no good data on ECT in patients with SAD, the indications for its use in can be extrapolated from nonseasonal depressive episodes, including nonresponse to alternative treatments, high suicide risk, psychotic depression, and previous positive response to ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that have specifically examined the efficacy of psychotherapy in SAD. However, two approaches to psychotherapy have shown efficacy in controlled clinical trials for the treatment of mild to moderate major depressive disorder, including interpersonal psychotherapy (IPT) and cognitive behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AHRQ guidelines have not listed psychotherapy as a first-line approach for obvious seasonal depression, since the focus of psychotherapy does not relate directly to the circadian dysregulation presumed to cause SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/32\">",
"     32",
"    </a>",
"    ]. Although this justification appears to contradict that used to support the use of some pharmacotherapy for SAD, it has not been established that seasonal depression in particular responds to these psychotherapies.",
"   </p>",
"   <p>",
"    Nevertheless, CBT or IPT are not contraindicated and can be considered for depressed patients who do not respond, refuse, or cannot participate in phototherapy or pharmacotherapy, and who have depressive episodes that are unipolar, nonpsychotic, and not so severe as to preclude therapeutic engagement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Combined therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While any of the above treatment modalities can be combined, there are limited data regarding combination therapy in SAD. In major depression, the balance of evidence favors combined pharmacotherapy and psychotherapy for patients with severe or recurrent symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial treatment of depression in adults\", section on 'Combined therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although advantages can be hypothesized for use of combined light therapy and psychotherapy (eg, increased compliance, reducing personal and interpersonal distress caused by the depression), trials are lacking. A preliminary randomized trial of light therapy combined with exercise (a form of behavioral activation) showed positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/64\">",
"     64",
"    </a>",
"    ]. Another preliminary randomized trial demonstrated benefit for the combination of CBT and light therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, although combined light therapy and pharmacotherapy may have unique benefits (eg, their concurrent use may ease side-effect complications of medication by allowing lower dosage), this approach awaits controlled study. It should be noted that current guidelines discourage the simultaneous use of light therapy and medication before either one, alone, has proven insufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22936/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/51/2866?source=see_link\">",
"       \"Patient information: Seasonal affective disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SAD is defined as recurring depression with seasonal onset and remission. Fall-onset (winter) SAD is more common than spring-onset SAD.",
"     </li>",
"     <li>",
"      Fall-onset SAD is characterized primarily by atypical symptoms of depression, while spring-onset SAD is associated with more typical features.",
"     </li>",
"     <li>",
"      The diagnosis of SAD is made by patients meeting the diagnostic criteria for depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"       table 1",
"      </a>",
"      ) with a seasonal pattern specifier (",
"      <a class=\"graphic graphic_table graphicRef55628 \" href=\"UTD.htm?3/21/3419\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Light therapy has proven effective in a limited number of small, placebo-controlled studies. The usual dose is 10,000 lux, beginning with one 10 to 15 minute session per day, gradually increasing to 30 to 45 minutes per day depending upon response. It may take four to six weeks to see a response, although some patients improve within days. Therapy is continued until sufficient daily light exposure is available through other sources, typically from springtime sun.",
"     </li>",
"     <li>",
"      Light therapy is considered first-line therapy in patients who are not severely suicidal, have medical reasons to avoid antidepressant drugs, have a history of a positive response to light therapy, or if the patient specifically requests it. Pharmacotherapy may be a better option in patients with significant functional impairment or who are at high suicide risk; for patients with a history of moderate to severe recurrent depression; and for patients who have had a prior positive response to antidepressants or mood stabilizers, who prefer pharmacotherapy, or who have failed other therapies.",
"     </li>",
"     <li>",
"      The indications for pharmacotherapy, electroconvulsive therapy, psychotherapy, and combined therapy are primarily extrapolated from studies of major depression, although a few placebo-controlled studies have found antidepressants to be effective for SAD. Psychotherapy and ECT are generally not considered first-line therapies for SAD, but they may be used in combination in some circumstances.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/1\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     Depression Guideline Panel. Depression in Primary Care: Treatment of Major Depression: Clinical Practice Guideline. US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR publication 93-0551, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/4\">",
"      Wehr TA, Sack DA, Rosenthal NE. Seasonal affective disorder with summer depression and winter hypomania. Am J Psychiatry 1987; 144:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/5\">",
"      Magnusson A. An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatr Scand 2000; 101:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/6\">",
"      Mersch PP, Middendorp HM, Bouhuys AL, et al. Seasonal affective disorder and latitude: a review of the literature. J Affect Disord 1999; 53:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/7\">",
"      Kasper S, Wehr TA, Bartko JJ, et al. Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Arch Gen Psychiatry 1989; 46:823.",
"     </a>",
"    </li>",
"    <li>",
"     Oren, DA, Rosenthal, NE. Seasonal affective disorders. In: Handbook of Affective Disorders, 2nd ed, Paykel, ES (Ed), Churchill Livingstone, London 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/9\">",
"      Partonen T, L&ouml;nnqvist J. Seasonal affective disorder. Lancet 1998; 352:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/10\">",
"      Blazer DG, Kessler RC, Swartz MS. Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. Br J Psychiatry 1998; 172:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/11\">",
"      Rosenthal NE, Carpenter CJ, James SP, et al. Seasonal affective disorder in children and adolescents. Am J Psychiatry 1986; 143:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/12\">",
"      Swedo SE, Pleeter JD, Richter DM, et al. Rates of seasonal affective disorder in children and adolescents. Am J Psychiatry 1995; 152:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/13\">",
"      Sher L. Genetic studies of seasonal affective disorder and seasonality. Compr Psychiatry 2001; 42:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/14\">",
"      Madden PA, Heath AC, Rosenthal NE, Martin NG. Seasonal changes in mood and behavior. The role of genetic factors. Arch Gen Psychiatry 1996; 53:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/15\">",
"      Checkley SA, Murphy DG, Abbas M, et al. Melatonin rhythms in seasonal affective disorder. Br J Psychiatry 1993; 163:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/16\">",
"      Coiro V, Volpi R, Marchesi C, et al. Abnormal serotonergic control of prolactin and cortisol secretion in patients with seasonal affective disorder. Psychoneuroendocrinology 1993; 18:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/17\">",
"      Schwartz PJ, Turner EH, Garcia-Borreguero D, et al. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. Psychiatry Res 1999; 86:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/18\">",
"      Schwartz PJ, Murphy DL, Wehr TA, et al. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. Arch Gen Psychiatry 1997; 54:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/19\">",
"      Joseph-Vanderpool JR, Jacobsen FM, Murphy DL, et al. Seasonal variation in behavioral responses to m-CPP in patients with seasonal affective disorder and controls. Biol Psychiatry 1993; 33:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/20\">",
"      Neumeister A, Turner EH, Matthews JR, et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998; 55:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/21\">",
"      Willeit M, Sitte HH, Thierry N, et al. Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology 2008; 33:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/22\">",
"      Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol Med 1998; 28:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/23\">",
"      Praschak-Rieder N, Willeit M, Wilson AA, et al. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008; 65:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/24\">",
"      Eagles JM. Seasonal affective disorder. Br J Psychiatry 2003; 182:174.",
"     </a>",
"    </li>",
"    <li>",
"     Beckham, EE; Leber, WR, Youll, LK. The diagnostic classification of depression. In: Handbook of Depression, 2nd ed, Beckham, EE, Leber, WR (Eds), Guilford Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/26\">",
"      Bauer MS, Dunner DL. Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM-IV. Compr Psychiatry 1993; 34:159.",
"     </a>",
"    </li>",
"    <li>",
"     van Praag, HM. \"Make-Believes\" in Psychiatry or The Perils of Progress, Brunner/Mazel, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/28\">",
"      Dilsaver SC, Del Medico VJ, Quadri A, Jaeckle S. Pharmacological responsiveness of winter depression. Psychopharmacol Bull 1990; 26:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/29\">",
"      Wehr TA, Rosenthal NE. Seasonality and affective illness. Am J Psychiatry 1989; 146:829.",
"     </a>",
"    </li>",
"    <li>",
"     Terman, M, Terman, JS. Light therapy for winter depression. In: Biologic Effects of Light, Holick, M, Kligman, AM (Eds), De Gruyter &amp; Co, Berlin 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/31\">",
"      Stewart JW, Quitkin FM, Terman M, Terman JS. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy. Psychiatry Res 1990; 33:121.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Health Care Policy &amp; Research: Depression in Primary Care. Clinical Practice Guidelines. U.S. Department of Health and Human Services, AHCPR, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/33\">",
"      Tam EM, Lam RW, Robertson HA, et al. Atypical depressive symptoms in seasonal and non-seasonal mood disorders. J Affect Disord 1997; 44:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/34\">",
"      Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984; 41:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/35\">",
"      Saeed SA, Bruce TJ. Seasonal affective disorders. Am Fam Physician 1998; 57:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/36\">",
"      Terman M, Terman JS, Ross DC. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 1998; 55:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/37\">",
"      Eastman CI, Young MA, Fogg LF, et al. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 1998; 55:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/38\">",
"      Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 162:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/39\">",
"      Terman JS, Terman M, Schlager D, et al. Efficacy of brief, intense light exposure for treatment of winter depression. Psychopharmacol Bull 1990; 26:3.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenthal, NE, Oren, DA. Light Therapy. In: Treatment of Psychiatric Disorders, 2nd ed, Gabbard, GO (Ed), American Psychiatric Press, Inc., Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/41\">",
"      Kr&auml;uchi K, Wirz-Justice A, Graw P. High intake of sweets late in the day predicts a rapid and persistent response to light therapy in winter depression. Psychiatry Res 1993; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/42\">",
"      Oren DA, Jacobsen FM, Wehr TA, et al. Predictors of response to phototherapy in seasonal affective disorder. Compr Psychiatry 1992; 33:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/43\">",
"      Rosenthal, NE. Light therapy: theory and practice. Primary Psychiatry 1994; Sep/Oct:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/44\">",
"      Lewy AJ, Bauer VK, Cutler NL, et al. Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 1998; 55:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/45\">",
"      Sack RL, Lewy AJ, White DM, et al. Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psychiatry 1990; 47:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/46\">",
"      Wirz-Justice A, Graw P, Kr&auml;uchi K, et al. Light therapy in seasonal affective disorder is independent of time of day or circadian phase. Arch Gen Psychiatry 1993; 50:929.",
"     </a>",
"    </li>",
"    <li>",
"     Bauer, MS, Kurtz, J, et al. Mood and behavioral effects of four-week light treatment in winter depressives and controls. Paper presented at the third annual meeting of the Society for Light Treatment and Biological Rhythms, Toronto, Ontario, Canada, June 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/48\">",
"      Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. J Clin Psychiatry 1999; 60:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/49\">",
"      Thaler K, Delivuk M, Chapman A, et al. Second-generation antidepressants for seasonal affective disorder. Cochrane Database Syst Rev 2011; :CD008591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/50\">",
"      Lam RW, Gorman CP, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995; 152:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/51\">",
"      Lingjaerde O, Reichborn-Kjennerud T, Haggag A, et al. Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Acta Psychiatr Scand 1993; 88:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/52\">",
"      Lam RW, Levitt AJ, Levitan RD, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006; 163:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/53\">",
"      Dilsaver SC, Qamar AB, Del Medico VJ. The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 1992; 53:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/54\">",
"      O'Rourke, D, Wurtman, J, Brezinski, A, et al. Treatment of seasonal affective disorder with D-fenfluramine. Ann NY Acad Sci 1987; 499:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/55\">",
"      Westrin A, Lam RW. Long-term and preventative treatment for seasonal affective disorder. CNS Drugs 2007; 21:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/56\">",
"      Leonhardt G, Wirz-Justice A, Kr&auml;uchi K, et al. Long-term follow-up of depression in seasonal affective disorder. Compr Psychiatry 1994; 35:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/57\">",
"      Sakamoto K, Nakadaira S, Kamo K, et al. A longitudinal follow-up study of seasonal affective disorder. Am J Psychiatry 1995; 152:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/58\">",
"      Thompson C, Raheja SK, King EA. A follow-up study of seasonal affective disorder. Br J Psychiatry 1995; 167:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/59\">",
"      Modell JG, Rosenthal NE, Harriett AE, et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 2005; 58:658.",
"     </a>",
"    </li>",
"    <li>",
"     Welch, CA. Electroconvulsive therapy. In: Treatment of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association, vol 3: 1803-1813, American Psychiatric Press, Washington, DC 1989.",
"    </li>",
"    <li>",
"     American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging: yA Task Force Report of the American Psychiatric Association. American Psychiatric Association, Washington, DC 1990.",
"    </li>",
"    <li>",
"     Markowitz, JC, Weissman, MM. Interpersonal psychotherapy. In: Handbook of Depression, 2nd ed, Beckham, EE, Leber, WR (Eds), Guilford Press, New York 1995.",
"    </li>",
"    <li>",
"     Sacco, WP, Beck, AT. Cognitive theory and therapy. In: Handbook of Depression, 2nd ed, Beckham, EE, Leber, WR (Eds), Guilford Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/64\">",
"      Lepp&auml;m&auml;ki SJ, Partonen TT, Hurme J, et al. Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids. J Clin Psychiatry 2002; 63:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22936/abstract/65\">",
"      Rohan KJ, Roecklein KA, Tierney Lindsey K, et al. A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder. J Consult Clin Psychol 2007; 75:489.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1705 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22936=[""].join("\n");
var outline_f22_25_22936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYNDROMAL VALIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Light therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Seasonal versus continuous pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Combined therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/21/3419\" title=\"table 2\">",
"      Criteria seasonal pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/5/23645\" title=\"table 3\">",
"      Light box retailers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/51/2866?source=related_link\">",
"      Patient information: Seasonal affective disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_25_22937="Elbow injuries in the young athlete";
var content_f22_25_22937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Elbow injuries in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22937/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22937/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22937/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22937/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22937/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/25/22937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to the elbow, forearm, and wrist account for more than 25 percent of all sports-related injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute injuries usually are related to falls, whereas chronic injuries occur with repetitive motion. Individuals who injure their elbows usually are throwers (eg, baseball and javelin), power grippers (eg, weight lifters, racquet athletes, gardeners, and carpenters), or those who use the elbow as a weightbearing joint (eg, gymnasts).",
"   </p>",
"   <p>",
"    The anatomy, skeletal maturity, clinical manifestations, and differential diagnosis of elbow complaints in young athletes are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elbow is made up of three interrelated joints (the radiocapitellar [radiohumeral], ulnohumeral, and radioulnar) and their stabilizing ligaments (",
"    <a class=\"graphic graphic_table graphicRef58982 \" href=\"UTD.htm?15/40/16011\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62086 graphicRef52653 \" href=\"UTD.htm?17/36/17990\">",
"     figure 1A-B",
"    </a>",
"    ). The radiocapitellar joint is formed laterally by the articulation of the capitellum of the humerus with the radial head. The ulnohumeral joint is formed medially by the articulation of the humerus with the coronoid process, trochlear notch, and olecranon of the ulna. The radioulnar joint is formed by the articulation of the radial head with the radial notch of the ulna and is surrounded by the annular ligament.",
"   </p>",
"   <p>",
"    The medial and lateral epicondyle and olecranon process of the humerus are the bony landmarks that are easily palpated. The medial epicondyle is the origin of the wrist and finger flexors and pronators. The lateral epicondyle is the origin of the wrist and finger extensors. The olecranon process is the insertion of the elbow extensors (triceps). The olecranon bursa is the most superficial of the 12 bursae surrounding the elbow.",
"   </p>",
"   <p>",
"    The muscles of the elbow and forearm can be divided according to their major actions:",
"    <span class=\"nowrap\">",
"     flexion/extension",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     supination/pronation.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Flexion/extension",
"      </span>",
"      of the elbow occurs at the ulnohumeral joint. Elbow flexion is controlled by the biceps brachii and brachialis muscles. The biceps brachii has insertions on the radial tuberosity and the forearm flexor fascia through the bicipital aponeurosis or lacertus fibrosis. The brachialis lies deep to the biceps and originates from the distal humerus and inserts on the coronoid process of the ulna. Elbow extension is primarily controlled by the triceps and some of the anconeus (",
"      <a class=\"graphic graphic_figure graphicRef67466 \" href=\"UTD.htm?31/40/32390\">",
"       figure 2",
"      </a>",
"      ). The normal arc of motion in children and adolescents ranges from -15 to 0 degrees in full extension to 150 degrees in flexion. At least 30 degrees of extension and 130 degrees of flexion are necessary for the activities of daily living.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Supination/pronation",
"      </span>",
"      of the forearm, with the radius rotating over the stationary ulna, occurs at the radiohumeral and proximal radioulnar articulations. The pronator quadratus and the pronator teres pronate the wrist (",
"      <a class=\"graphic graphic_figure graphicRef80260 \" href=\"UTD.htm?27/29/28118\">",
"       figure 3",
"      </a>",
"      ). The pronator quadratus runs obliquely from the distal ulna to the more distal radius. The pronator teres originates from the medial epicondyle and the proximal ulna and inserts on the lateral midshaft of the radius. The supinators are much stronger than the pronators and include the supinator and the biceps brachii. The supinator originates on the proximal posterior ulna and inserts on the proximal radius. The biceps brachii has insertions on the radial tuberosity and the forearm flexor fascia through the bicipital aponeurosis or lacertus fibrosis. The normal range of motion is approximately 90 degrees for both supination and pronation. At least 50 degrees of pronation and supination are necessary for the activities of daily living.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sensation and voluntary movement of the elbow and wrist are under control of the median, radial, ulnar, and musculocutaneous nerves (",
"    <a class=\"graphic graphic_table graphicRef53902 \" href=\"UTD.htm?24/11/24763\">",
"     table 2",
"    </a>",
"    ). The median nerve crosses the elbow in the antecubital fossa just medial to the biceps tendon and brachial artery and primarily innervates the wrist",
"    <span class=\"nowrap\">",
"     flexor/pronators,",
"    </span>",
"    finger flexors, and thenar muscles (",
"    <a class=\"graphic graphic_figure graphicRef80260 \" href=\"UTD.htm?27/29/28118\">",
"     figure 3",
"    </a>",
"    ). The ulnar nerve crosses the elbow posteriorly and medially in the cubital tunnel of the humerus. The radial nerve crosses the elbow anterior to the lateral epicondyle and innervates the wrist extensors and supinators (",
"    <a class=\"graphic graphic_figure graphicRef67466 \" href=\"UTD.htm?31/40/32390\">",
"     figure 2",
"    </a>",
"    ). The musculocutaneous nerve crosses the elbow in the lateral antecubital fossa and innervates the elbow flexors.",
"   </p>",
"   <p>",
"    The brachial artery is the major artery that transverses the antecubital fossa; injury to the brachial artery will cause radiating pain, decreased skin temperature, decreased pulses, and pallor of the distal arm and may result in Volkmann's contracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SKELETAL MATURITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal maturity in children and adolescents is classified according to the appearance and fusion of the secondary ossification centers of the distal humerus and proximal radius and ulna (",
"    <a class=\"graphic graphic_figure graphicRef73818 graphicRef79600 \" href=\"UTD.htm?28/1/28695\">",
"     figure 4A-B",
"    </a>",
"    ). Childhood, in relation to bone age, ends with the appearance of all the secondary ossification centers; adolescence with the fusion of all secondary ossifications centers; and young adulthood with the completion of all bone growth.",
"   </p>",
"   <p>",
"    The appearance of these ossification centers proceeds in an orderly fashion, usually occurring approximately one year earlier in girls than in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/2\">",
"     2",
"    </a>",
"    ]. The mnemonic to remember the order of their appearance is CRITOE (",
"    <a class=\"graphic graphic_table graphicRef61591 \" href=\"UTD.htm?12/19/12604\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The secondary ossification centers fuse to create the mature bony elbow. The lateral epicondyle, trochlear, and capitellar centers fuse first; this unit then fuses with the distal humerus; the last fusion occurs at the medial epicondyle. Similar to the appearance of the ossification centers, fusion proceeds in an orderly fashion and usually occurs earlier in girls than in boys (",
"    <a class=\"graphic graphic_table graphicRef61591 \" href=\"UTD.htm?12/19/12604\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information obtained in the history will help to narrow the differential diagnosis for athletes with elbow complaints. The crucial elements of the history may vary depending upon whether the complaints are acute or chronic. Acute complaints begin with a discrete event; chronic complaints have an insidious onset and a longer duration of symptoms. The clinician should also ask about neck complaints which may be caused by significant cervical injuries with pain radiating to the elbow. Past medical history, family history, and review of systems must be included to rule out other causes of joint pain and swelling (eg, arthritis or other rheumatologic disorder, gout, infection, hemoglobinopathy, bleeding disorder, or neoplasm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute elbow injuries can be caused by contact trauma, valgus trauma with the hand planted, or a fall on an outstretched hand. Information that is important to know is whether the athlete felt a pop, crack, or snap sensation at the time of the injury; whether they had or continue to have locking, catching, shifting, or instability of the elbow; and whether they have any distal neurovascular complaints (eg, weakness, tingling, paresthesias, coolness).",
"   </p>",
"   <p>",
"    Chronic elbow injuries typically are caused by repetitive activity or start of a new activity. The frequency, intensity, duration, progression, and mechanics of the activity should be determined. This determination is particularly true for throwing because it causes medial traction and lateral compression of the elbow. In addition, the elbow is the weakest link in the kinetic chain, the connection of joints from the foot through the arm that is used to throw an object; biomechanical change especially in the shoulder and scapula caused by an injury can cause abnormal mechanics and stress that will result in secondary injury at the elbow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Additional questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above questions regarding joint mobility and stability, the following are important points about which to inquire:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain &ndash; The location, quality, radiation, and intensity of pain (eg, on a 10-point scale) as well as aggravating and alleviating factors.",
"     </li>",
"     <li>",
"      Neurovascular complaints &ndash; The presence of weakness, tingling, paresthesias, or coolness.",
"     </li>",
"     <li>",
"      Interventions &ndash; Any interventions the athlete has tried to improve the symptoms (eg, medications, application of heat or cold, activity modification, rehabilitation, or surgery) and whether they were successful.",
"     </li>",
"     <li>",
"      Functional performance &ndash; Has the athlete experienced a change in functional performance? Throwers with medial epicondyle apophysitis, for example, may complain initially of loss of control (eg, the tendency of the ball to sail higher than the intended target), followed by loss of endurance, pain, and finally loss of velocity.",
"     </li>",
"     <li>",
"      Mechanical sensations &ndash; Popping, locking, catching, or \"loose bodies.\"",
"     </li>",
"     <li>",
"      Recent illnesses &ndash; Athletes being treated with quinolone antibiotics have been noted to have an increased risk of tendinitis and tendon rupture. The athlete should also be asked about recent illness because arthritis is a well-recognized and relatively common accompaniment to infection by a number of viruses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H29#H29\">",
"       \"Fluoroquinolones\", section on 'Tendinopathy and tendon rupture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"       \"Specific viruses that cause arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Age &ndash; The age and bone maturity of the athlete affect the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef55341 \" href=\"UTD.htm?8/4/8267\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents who have elbow complaints must undergo a thorough history and screening examination of the neck and shoulder in addition to the elbow. Neck and shoulder injuries can manifest with symptoms at the elbow.",
"   </p>",
"   <p>",
"    The key components of the physical examination of the elbow are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the elbow includes observation for ecchymosis, swelling, muscular atrophy, and breaks in the skin that may indicate an open fracture or entry point for infection. The following normal relationships should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The angle between the long axes of the humerus and the forearm (the carrying angle) varies between 5&ordm; and 20&ordm; and usually is greater in girls than in boys [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/3\">",
"       3",
"      </a>",
"      ]. Alterations in this angle may indicate previous fractures.",
"     </li>",
"     <li>",
"      The lateral and medial epicondyle and olecranon process form an isosceles triangle with the elbow in 90&ordm; flexion and a straight line with the elbow in full extension. This relationship is lost in posterior elbow dislocations. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Posterior elbow dislocation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The radial head, tip of the olecranon, and the lateral epicondyle normally form an equilateral triangle with the elbow in 90 degrees flexion. Alterations in this relationship may indicate fracture of the radial head, olecranon, or the lateral epicondyle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination of the elbow should include palpation of the following structures in each location:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior elbow &ndash; Biceps muscle and distal tendon",
"     </li>",
"     <li>",
"      Posterior elbow &ndash; Olecranon process, olecranon bursa, epiphyseal plate and olecranon fossa, triceps brachii",
"     </li>",
"     <li>",
"      Medial elbow &ndash; Medial epicondyle, medial epicondyle apophysis and epiphyseal plate, ulnar collateral ligament",
"     </li>",
"     <li>",
"      Lateral elbow &ndash; Lateral epicondyle, radial head (best felt with the elbow at 90 degrees and supinating and pronating the forearm), and capitellum",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurovascular examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurovascular examination of the elbow and distal extremity should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sensation and strength testing in the distribution of the median, radial, ulnar, and musculocutaneous nerves (",
"      <a class=\"graphic graphic_table graphicRef53902 \" href=\"UTD.htm?24/11/24763\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deep tendon reflexes of the biceps (C5), brachioradialis (C6), and triceps (C7)",
"     </li>",
"     <li>",
"      Palpation of the brachial, radial, and ulnar pulses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of motion and strength of the elbow and wrist should be examined (",
"    <a class=\"graphic graphic_table graphicRef70587 graphicRef54423 \" href=\"UTD.htm?4/13/4317\">",
"     table 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Provocative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several confirmatory tests may be warranted in patients with a suspected diagnosis based upon the findings of the history and physical examination. They include varus and valgus testing of the medial complex, moving valgus stress test, the pronator compression test, and the OK and Tinel signs (",
"    <a class=\"graphic graphic_table graphicRef60590 \" href=\"UTD.htm?2/4/2125\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for elbow pain in the young athlete is organized according to the location of pain (",
"    <a class=\"graphic graphic_table graphicRef68293 \" href=\"UTD.htm?38/53/39772\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anterior elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior elbow pain can be caused by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biceps tendinitis or rupture",
"     </li>",
"     <li>",
"      Anterior capsule strain",
"     </li>",
"     <li>",
"      Median nerve compression syndromes",
"     </li>",
"     <li>",
"      Radiculopathy of C5-6",
"     </li>",
"     <li>",
"      Occult fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Anterior capsule strain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior capsule strain occurs after a hyperextension injury from a fall, with repetitive extension motions (eg, the follow-through of a pitcher), or during a posterior subluxation injury with spontaneous relocation.",
"   </p>",
"   <p>",
"    Physical examination may show a fibrotic flexion contracture. The differential diagnosis must include anything that could restrict full extension, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior olecranon impingement, especially in throwers. These athletes usually have posterior pain at the end of their range with full extension.",
"     </li>",
"     <li>",
"      Loose body, especially in patients with osteoarthritis. Loose bodies may be palpable or visible on elbow radiographs (three views).",
"     </li>",
"     <li>",
"      Distal biceps tendinitis and muscle spasm. These athletes have weakness in elbow flexion and altered accessory motion in the proximal radius.",
"     </li>",
"     <li>",
"      Osteochondritis dissecans (osteonecrosis) may be apparent on plain radiographs or MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of anterior capsule strain entails protection from repeated injury and range of motion exercises to avoid contracture. Splinting in a dynamic, hinged or static, progressive brace can be used for six months before considering operative management for the joint stiffness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Median nerve compression syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Median nerve compression syndromes present with palmar side proximal forearm pain, particularly with repeated pronation, and with numbness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weakness in the median nerve distribution.",
"   </p>",
"   <p>",
"    Compression and tension on the proximal median nerve occurs most frequently in either the pronator teres (common median nerve) or the proximal flexor digitorum superficialis (anterior interosseous branch of median nerve); the location of impingement is determined by the physical examination as described above. Children and adolescents with the anterior interosseous nerve (AION) syndrome initially have proximal forearm pain followed by weakness in the hand with no sensory deficits. On physical examination they have a weak \"OK sign\"",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a lack of DIP flexion in OK sign (more of a pincer grasp than an OK sign) (",
"    <a class=\"graphic graphic_picture graphicRef52203 \" href=\"UTD.htm?25/33/26142\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other etiologies of median nerve symptoms include a C6 radiculopathy, carpal tunnel syndrome, occult fracture, interphalangeal joint pathology, and rupture of the flexor pollicis.",
"   </p>",
"   <p>",
"    The treatment for median nerve compression syndromes includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relative rest (avoidance of pain-producing activities: elbow flexion, wrist pronation, and grip activation)",
"     </li>",
"     <li>",
"      Medications (NSAIDs)",
"     </li>",
"     <li>",
"      Immobilization for 7 to 10 days",
"     </li>",
"     <li>",
"      Progressive stretching and strengthening of elbow flexors, wrist flexors and pronators, and grip exercises",
"     </li>",
"     <li>",
"      Neurodiagnostic evaluation may be helpful in localizing the lesion and degree of nerve injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If no interval improvement is seen in six to eight weeks, surgical decompression should be considered. However, AION have recovered spontaneously up to 12 months after onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Posterior elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior elbow pain can be caused by (",
"    <a class=\"graphic graphic_table graphicRef68293 \" href=\"UTD.htm?38/53/39772\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Posterior elbow dislocation",
"     </li>",
"     <li>",
"      Olecranon bursitis",
"     </li>",
"     <li>",
"      Triceps tendinitis or rupture",
"     </li>",
"     <li>",
"      Osteophytic degeneration of the tendon",
"     </li>",
"     <li>",
"      Valgus extension",
"      <span class=\"nowrap\">",
"       overload/olecranon",
"      </span>",
"      impingement syndrome",
"     </li>",
"     <li>",
"      Radiculopathy of C7, T1-2",
"     </li>",
"     <li>",
"      Olecranon",
"      <span class=\"nowrap\">",
"       apophysitis/stress",
"      </span>",
"      fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Posterior elbow dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior elbow dislocation is the most common dislocation in children younger than 10 years of age and the second most common in adults, after shoulder dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/5\">",
"     5",
"    </a>",
"    ]. Posterior elbow dislocations account for approximately 5 percent of all elbow injuries in children; 64 percent have associated fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/6\">",
"     6",
"    </a>",
"    ]. The peak incidence occurs at 12 years of age.",
"   </p>",
"   <p>",
"    Posterior elbow dislocations usually occur after a fall or a twisting injury to the elbow. Pain and obvious deformity aid in the diagnosis. The olecranon is prominent posteriorly, and the normal triangular relationship between the olecranon and the medial and lateral epicondyles is disrupted. Radiographs should be obtained to rule out associated fracture.",
"   </p>",
"   <p>",
"    Neurovascular complications are relatively uncommon, but they are imperative to diagnose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/7\">",
"     7",
"    </a>",
"    ]. Transient ulnar neuropathy, with the classic findings of altered sensation involving the ring and little fingers and hypothenar eminence, occurs in approximately 10 percent of cases. Median nerve injury occurs less frequently and is characterized by severe pain that is not relieved by elbow relocation. Brachial artery injuries, a rare complication of posterior elbow dislocation, cause radiating pain, decreased skin temperature, decreased pulse, and pallor in the distal arm. Early microvascular repair of brachial artery injuries decreases the long-term sequelae, including the development of contracture of the flexor muscles and median and ulnar nerve palsies (Volkmann's ischemic contracture) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unreduced dislocations should be immobilized \"as is\" pending evaluation by an experienced practitioner [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/10\">",
"     10",
"    </a>",
"    ]. Posterior elbow dislocations typically are reduced by an experienced practitioner. Multiple techniques are effective in the reduction of the uncomplicated posterior dislocation. The common components include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Supination of the forearm",
"     </li>",
"     <li>",
"      Elbow flexed to 90 degrees",
"     </li>",
"     <li>",
"      Counter for status stabilizes the humerus",
"     </li>",
"     <li>",
"      Gentle axial traction on the forearm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If not successful, adding more elbow flexion, volar directed pressure on the olecranon process as well as gentle pressure on the proximal forearm in a volar direction may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/11\">",
"     11",
"    </a>",
"    ]. Splint immobilization may be needed for 7 to 10 days, with early range of motion exercises. The arm then should be placed in a sling for two to three weeks. Gentle elbow flexion and extension exercises can begin at three to five weeks. Long-term functional outcomes are very good [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Olecranon bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olecranon bursitis may be seen in repetitive throwers (eg, darts) or in children and adolescents who have direct contact trauma or friction to the olecranon (eg, a fall on a hard surface, wrestling). A boggy swelling over the olecranon that can be as large as an egg will be present on physical examination. Other diagnostic considerations include septic",
"    <span class=\"nowrap\">",
"     bursitis/arthritis,",
"    </span>",
"    gout, and triceps tendinitis.",
"   </p>",
"   <p>",
"    Treatment for olecranon bursitis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protection and compression with an elbow pad",
"     </li>",
"     <li>",
"      Application of ice as long as the elbow is swollen",
"     </li>",
"     <li>",
"      NSAIDs as long as the elbow is painful",
"     </li>",
"     <li>",
"      Diagnostic or therapeutic aspiration if indicated",
"     </li>",
"     <li>",
"      Antibiotic therapy if infection is suspected (penicillinase resistant penicillin)",
"     </li>",
"     <li>",
"      Bursectomy for chronic recalcitrant cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Triceps tendinitis or rupture (snapping tendonitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas triceps tendinitis is relatively common, rupture is rare in children and adolescents unless associated with systemic lupus erythematosus, hyperparathyroidism, or xanthomatous degeneration or the athlete is receiving systemic or local corticosteroids, anabolic steroids, or quinolone antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=see_link&amp;anchor=H493467#H493467\">",
"     \"Use of androgens and other hormones to enhance athletic performance\", section on 'Tendon rupture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H29#H29\">",
"     \"Fluoroquinolones\", section on 'Tendinopathy and tendon rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The athlete may complain of a snapping sensation along the medial border of the elbow where the triceps snaps over the medial epicondyle at a greater than 135 degrees of flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar complaints also may occur in athletes who have a subluxating ulnar nerve, but it usually occurs at 90 degrees of flexion. Physical examination may show swelling and pain to palpation over the distal triceps and posterior olecranon, pain with resisted extension, and decreased range of motion in elbow extension. Athletes who have triceps rupture may have a palpable defect, usually at the tendon's insertion on the olecranon, and decreased strength in extension of the elbow. Olecranon impingement and osteophytic degeneration of the tendon may have similar findings.",
"   </p>",
"   <p>",
"    Tendinitis can be treated with proper mechanics, relative rest, ice, NSAIDs, and a stretching and strengthening program. Corticosteroid injections should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/15\">",
"     15",
"    </a>",
"    ]. Complete rupture requires surgical repair, whereas partial tears require splint immobilization for four weeks with 30 degrees of elbow flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Valgus extension overload/olecranon impingement syndrome (VEO/OIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;VEO/OIS",
"    results from forceful repeated hyperextension, such as boxer's jabs or throwers with poor follow-through. Repetitive valgus stress at the elbow can stretch the ulnar collateral ligament, leading to medial elbow instability. Repetitive valgus extension loads, in the presence of medial instability, cause the medial olecranon to rotate internally and rub against the medial olecranon fossa",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stretch the ulnar nerve.",
"   </p>",
"   <p>",
"    Olecranon impingement, which can occur without medial instability, may result in osteophyte formation, loose bodies, and fracture. Insidious onset of posterior medial elbow pain with locking and catching sensation in the elbow is the hallmark complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/17\">",
"     17",
"    </a>",
"    ], but is important to rule out osteochondritis dissecans of the capitellum.",
"   </p>",
"   <p>",
"    On physical examination the athlete with",
"    <span class=\"nowrap\">",
"     VEO/OIS",
"    </span>",
"    has pain to palpation along the medial border of the olecranon fossa, pain with valgus of the elbow in extension, and possible flexion contracture. Their symptoms are worsened by passive hyperextension of the elbow. Children and adolescents who have triceps tendinitis may have similar symptoms, but their pain to palpation is posterior rather than medial and they do not have pain with passive hyperextension of the elbow.",
"   </p>",
"   <p>",
"    Radiographs may be helpful in athletes with long-standing symptoms or to rule out other diagnoses such as olecranon or medial epicondyle stress fracture.",
"   </p>",
"   <p>",
"    Treatment of",
"    <span class=\"nowrap\">",
"     VEO/OIS",
"    </span>",
"    includes initial conservative management with no throwing for three to six months and rehabilitation to strengthen the medial elbow to provide dynamic support to elbow valgus with balanced dynamic firing patterns of the biceps and triceps. Surgery may be necessary to treat the underlying medial instability or for treatment of osteophyte and chondromalacia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Medial elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medial elbow pain can be caused by (",
"    <a class=\"graphic graphic_table graphicRef68293 \" href=\"UTD.htm?38/53/39772\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medial epicondylitis (golfer's elbow)",
"     </li>",
"     <li>",
"      Ulnar neuritis",
"     </li>",
"     <li>",
"      Medial epicondyle avulsion fracture",
"     </li>",
"     <li>",
"      Medial epicondyle traction apophysitis",
"     </li>",
"     <li>",
"      Ulnar collateral ligament tear",
"     </li>",
"     <li>",
"      Radiculopathy of C8, T1",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Medial epicondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medial epicondylitis, also known as golfer's elbow, results from improper overuse of the forearm pronators and wrist flexors. This occurs primarily in tennis players who have a twist American serve and golfers whose trail arm lacks elbow extension at ball impact [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/18\">",
"     18",
"    </a>",
"    ]. It is much less common than is lateral epicondylitis.",
"   </p>",
"   <p>",
"    Throwers are particularly susceptible to this injury because the flexor-pronator muscles are maximally involved during the acceleration phase of the throwing motion. Each pitch has the potential to generate more tensile force than the ulnar collateral ligament can tolerate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/19\">",
"     19",
"    </a>",
"    ]. This emphasizes the importance of muscular dynamic stabilizers in the throwing motion. Athletes with medial epicondylitis complain of aching pain around the medial epicondyle while performing certain movements; the intensity of the pain increases with the chronicity of symptoms.",
"   </p>",
"   <p>",
"    Physical examination demonstrates pain to palpation over the medial epicondyle and pain with resisted wrist flexion (",
"    <a class=\"graphic graphic_picture graphicRef77615 \" href=\"UTD.htm?27/23/28019\">",
"     picture 2",
"    </a>",
"    ) and pronation. Considering ulnar neuritis and medial instability as sources of the pain is important.",
"   </p>",
"   <p>",
"    The treatment of medial epicondylitis includes technical modification of the activity, relative rest, stretching and strengthening of flexor forearm groups, and the use of other modalities (NSAIDs, ice, and physical therapy) to decrease irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Ulnar neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar neuritis is the most common nerve injury involving the elbow. It has numerous etiologies, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct trauma (from a fall or leaning on the elbows)",
"     </li>",
"     <li>",
"      Repetitive traction (eg, the acceleration phase of throwing)",
"     </li>",
"     <li>",
"      Exaggerated valgus from medial instability of the elbow [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged elbow hyperflexion (eg, talking on the phone)",
"     </li>",
"     <li>",
"      Compression from muscle hypertrophy (eg, triceps, anconeus muscles in throwers and weight lifters)",
"     </li>",
"     <li>",
"      Friction from ulnar nerve subluxation (16 percent of the general population have this hypermobility of the ulnar nerve)",
"     </li>",
"     <li>",
"      Upper limb neural tension from abnormal muscle spasm and altered by mechanics [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain at the posterior medial elbow that radiates proximally to the medial bicep-triceps interval and distally to the palm and dorsum of the hand and the fifth and ulnar fourth finger are the hallmarks of ulnar nerve irritation. The pain is reproduced with the Tinel maneuver (",
"    <a class=\"graphic graphic_picture graphicRef53954 \" href=\"UTD.htm?7/46/7904\">",
"     picture 3",
"    </a>",
"    ) and prolonged (three minutes) elbow flexion and wrist extension.",
"   </p>",
"   <p>",
"    Valgus instability at 30 degrees of flexion is an important test, particularly in throwers. Foraminal loading to stress the C8 nerve root will help to exclude cervical pathology. This test is performed by pushing down on the top of the head with gentle force.",
"   </p>",
"   <p>",
"    Radiographs may show medial osteophytic change. Electromyography and nerve conduction velocity studies correlate with the severity of the disease and may be positive in 40 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial management is similar to that of an ulnar collateral ligament strain (see below) if medial instability is present. The components of treatment for ulnar neuritis without medial instability include avoidance of exacerbating activities, use of elbow pads to decrease incidental trauma, and use of elbow splints to keep arms fully extended during sleep.",
"   </p>",
"   <p>",
"    Antiinflammatory agents and physical therapy may be helpful. Recalcitrant cases (lasting three to six months) or those with motor deficits may need surgery to free the ulnar nerve. Numerous techniques, including anterior transposition, medical epicondylectomy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in situ decompression, can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Little league elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little league elbow is the name used to describe a group of elbow problems related to the stress of throwing in young athletes. Throwing can cause medial symptoms as well as lateral and posterior symptoms. The medial symptoms are related to the repetitive valgus distraction forces on the medial elbow. Microtrauma from overuse or improper throwing mechanics (opening up too soon so the throwing arm trails behind the trunk rotation) can cause injury. The skeletal maturity of the athlete affects the type of injury (",
"    <a class=\"graphic graphic_table graphicRef55341 \" href=\"UTD.htm?8/4/8267\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for injury requiring surgery on their elbow or shoulder were discerned by comparing the throwing habits of injured and uninjured young pitchers (mean age 18 years) and included [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Throwing frequently when arm was fatigued (OR = 36, 95% CI 6.0-221.0)",
"     </li>",
"     <li>",
"      Throwing more than 80 pitches per appearance (OR = 4.0, 95% CI 1.4-11.0)",
"     </li>",
"     <li>",
"      Pitching for more than eight months per year(OR = 5.0, 95% CI 1.4-18.3)",
"     </li>",
"     <li>",
"      Fast ball faster than 85 mph(OR = 3, 95% CI 0.9-7.0)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 10 year prospective study of young pitchers (age 9 to 14), 5 percent required",
"    <span class=\"nowrap\">",
"     elbow/shoulder",
"    </span>",
"    surgery or had injuries that for them to stop playing baseball. Only 2.2 percent were still pitching at the end of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The total number of pitches thrown by children in youth baseball (eg, Little League) may be more important than the type of pitch thrown (eg, curveball versus fastball) in predicting elbow injury, given that biomechanical forces required to throw a curveball are actually less than for a fastball [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, increased frequencies of elbow and shoulder pain have been described in children who throw breaking pitches (curveballs or sliders) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Committee on Sports Medicine and Fitness of the American Academy of Pediatrics (AAP) and Little League Baseball recommend that preventive measures should be employed to prevent these injuries in young pitchers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These measures include restriction of the amount of pitching (eg, limit pitches per game, months per year spent pitching); instruction in proper throwing techniques; avoidance of pitching when the arm hurts or is fatigued; and education of coaches, parents, and children to facilitate early diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Medial epicondyle apophysitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medial epicondyle has the longest exposure to medial distraction forces in the elbow because it is the last ossification center to close. Thus, medial epicondyle apophysitis is the most common elbow injury during childhood (before the appearance of all the secondary ossification centers).",
"   </p>",
"   <p>",
"    Athletes with medial epicondyle apophysitis complain of medial elbow pain, initially after throwing, that progresses to persistent pain.",
"   </p>",
"   <p>",
"    Physical examination demonstrates pain to palpation of the medial epicondyle that is exacerbated by resisted wrist flexion (",
"    <a class=\"graphic graphic_picture graphicRef77615 \" href=\"UTD.htm?27/23/28019\">",
"     picture 2",
"    </a>",
"    ) and valgus testing of the elbow. Elbow extension may be limited. Radiographs demonstrate an open ossification center without separation.",
"   </p>",
"   <p>",
"    Treatment includes no throwing for four to six weeks, as well as symptomatic treatment with ice and NSAIDs. Correction of throwing mechanics and a progressive throwing program over the subsequent six to eight weeks will help the athlete to return to play. In addition, a position change from pitcher (typically 15 to 30 throws per inning) may help the player to avoid overloading the elbow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Medial epicondyle avulsion fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medial epicondyle avulsion fractures are the most common elbow injury during adolescence (between the appearance and the fusion of the secondary ossification centers). Athletes may report that they felt a sudden \"pop\" of the elbow during the throw, followed by acute onset of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/32\">",
"     32",
"    </a>",
"    ]. The physical findings in athletes with medial epicondyle avulsion are similar to those in apophysitis. However, radiographs demonstrate a separation of the medial epicondyle apophysis.",
"   </p>",
"   <p>",
"    Treatment of minimally displaced (&lt;2 mm) medial epicondyle avulsion fractures involves splint immobilization for six weeks. Early range of motion exercises out of the splint can be started once the athlete can perform them without pain (usually one to two weeks). Referral for surgical intervention is advised if greater than 2 mm displacement of the apophysis has occurred or if concomitant ulnar nerve findings are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Ulnar collateral ligament tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar collateral ligament tears occur in the skeletally mature thrower, as well as in wrestlers, gymnasts, or football players who sustain traumatic valgus injury from a fall on an outstretched arm or a tackle while the hand is planted. The anterior bundle of the ulnar collateral ligament is the primary restraint to valgus forces at the elbow during the throwing motion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/33\">",
"     33",
"    </a>",
"    ]. Of throwers with a ruptured ulnar collateral ligament, 50 percent had a single catastrophic event; most had some symptoms before the event [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, valgus stress at 30 degrees of elbow flexion reproduces medial pain and instability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/35\">",
"     35",
"    </a>",
"    ]. Ulnar collateral ligament tears may be seen on stress radiographs with the application of valgus force. Magnetic resonance imaging (MRI) with contrast arthrography is sensitive for both partial and full thickness ligament injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/36\">",
"     36",
"    </a>",
"    ]. The &ldquo;moving valgus stress test&rdquo; can increase the sensitivity of the physical exam for detecting UCL injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment includes conservative management for at least six months with no throwing activities. Ice and NSAIDs can be used to control symptoms; the ulnar nerve, which runs behind the medial epicondyle, should be avoided during the application of ice because it can sustain thermal injury from prolonged exposure. The associated strength deficits should be addressed through rehabilitation. An eight-week progressive throwing program after the six-month rest will test the success of conservative management. If symptoms return, surgical intervention may be necessary (ulnar collateral ligament reconstruction, also known as Tommy John surgery).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Lateral elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of lateral elbow pain include (",
"    <a class=\"graphic graphic_table graphicRef68293 \" href=\"UTD.htm?38/53/39772\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lateral epicondylitis",
"     </li>",
"     <li>",
"      Radial nerve syndromes",
"     </li>",
"     <li>",
"      Panner's disease",
"     </li>",
"     <li>",
"      Osteochondritis dissecans of the capitellum",
"     </li>",
"     <li>",
"      Musculocutaneous nerve entrapment",
"     </li>",
"     <li>",
"      Radiculopathy of C5, 6",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Lateral epicondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral epicondylitis accounts for 7 percent of all sports injuries and is the most common sports-related problem at the elbow. It affects 40 to 50 percent of recreational tennis players during their career and occurs equally in males and females. Predisposing factors include high tension on the racket strings, improper-sized grip, and leading the backhand with the elbow.",
"   </p>",
"   <p>",
"    Lateral epicondylitis also is seen in computer users from repetitive wrist extension for keyboard use. Repetitive wrist extension causes degenerative inflammation of the wrist extensors that insert on the lateral epicondyle, most commonly the extensor carpi radialis brevis. The degenerative nature of the problem is supported by the increased prevalence of lateral epicondylitis with increased age.",
"   </p>",
"   <p>",
"    Patients complain of sharp pain at the lateral epicondyle that may radiate down the extensor forearm. They also may complain of wrist weakness. Pain to palpation over the lateral epicondyle that worsens with resisted wrist extension (",
"    <a class=\"graphic graphic_picture graphicRef63769 \" href=\"UTD.htm?1/20/1346\">",
"     picture 4",
"    </a>",
"    ) or passive wrist flexion with the elbow extended is demonstrated on physical examination.",
"   </p>",
"   <p>",
"    Initial treatment includes ice, NSAIDs, use of a counterforce brace, rehabilitation to stretch and strengthen the wrist extensors and grip muscles, and curtailing exacerbating activities. Exacerbating activities include hand shaking, opening jars and doors, and carrying objects with the wrist extended (as with the plastic bags from the grocery store). Wrist splint immobilization and corticosteroid injection may be helpful if the above measures are not effective. Persistent pain despite aggressive treatment may indicate a concomitant posterior interosseous nerve injury. Surgical decompression should be considered if conservative management fails or the residual symptoms are not acceptable after one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Radial nerve syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the radial nerve enters the antecubital fossa laterally, it divides into the posterior interosseous branch and the superficial radial nerve.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior interosseous nerve syndromes occur from irritation of the nerve typically caused by repetitive pronation and supination, direct trauma, or mass lesion from tumor or previous injury. Posterior interosseous nerve syndromes coexist in 5 percent of lateral epicondylitis cases and may explain lack of response to conservative measures in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Lateral epicondylitis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Physical examination demonstrates lateral elbow pain, usually distal to the lateral epicondyle, and weakness in the wrist, thumb, and finger extensors. These findings also may be present in patients who have diabetes, polyarteritis nodosa, and heavy metal poisoning. NSAIDS and avoidance of irritating movements can help control symptoms, but posterior interosseous nerve syndromes may require surgical decompression for definitive treatment.",
"     </li>",
"     <li>",
"      Radial tunnel syndrome occurs because of compression of the superficial radial nerve by structures in or near the radial tunnel, including the supinator, extensor carpi radialis brevis, and brachioradialis. It may be caused by repetitive pronation and supination, direct trauma, ganglion, or bony lesion of the radial head. Complaints include deep, dull ache distal to the lateral epicondyle that may be worse at night. Weakness and sensory changes are uncommon. Physical examination demonstrates pain to palpation over the extensor mass about four finger breadths distal to lateral epicondyle and pain with resisted forearm supination. Pain may be reproduced by resisted extension of the middle finger with the elbow in extension (long finger extension test) (",
"      <a class=\"graphic graphic_picture graphicRef56713 \" href=\"UTD.htm?18/19/18751\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Radiocapitellar joint injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiocapitellar joint injuries are common in throwers because of the compression associated with the acceleration phase of throwing and in gymnasts because the elbow is made to be a weightbearing joint [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Panner disease",
"      </strong>",
"      &ndash; Panner disease is an osteochondrosis of the capitellum. Osteochondrosis is a degenerative disorder of the growing epiphysis and its secondary ossification centers. It occurs most frequently in boys between 7 and 12 years of age and is almost always unilateral and in the dominant (ie, throwing) arm. The symptoms include sudden onset of lateral elbow tenderness with decreased range of motion in extension. Appreciable swelling may occur. Radiographs will show fragmentation (areas of sclerosis and rarefaction) of the capitellum with an irregular joint surface. The mainstay of treatment is avoidance of elbow stress until radiographic and physical examination provides evidence of full healing (usually 6 to 12 weeks). Because of the young athlete's ability to regenerate and recalcify, the capitellum has excellent potential for normal anatomic and functional healing [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Osteochondritis dissecans",
"      </strong>",
"      &ndash; Osteochondritis dissecans (OCD) is an avascular necrosis of the articular cartilage and underlying subchondral bone that occurs in the capitellum in older athletes (age 13 to 15 years), particularly gymnasts, baseball pitchers, and American football quarterbacks. The symptoms include dull, poorly localized lateral elbow pain with decreased range of motion. Mechanical symptoms of popping, locking, and catching usually are late symptoms. Plain radiographs show flattening of the capitellum with a crater and subchondral sclerosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85769 \" href=\"UTD.htm?2/41/2704\">",
"       image 1",
"      </a>",
"      ), but may be normal initially. Magnetic resonance imaging is helpful in early detection and staging of the lesion. The diagnosis and treatment of OCD of the elbow is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H2510199#H2510199\">",
"       \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=see_link\">",
"       \"Management of osteochondritis dissecans (OCD)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Musculocutaneous nerve entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculocutaneous nerve entrapment can present with vague pain and dysesthesia in the anterior lateral portion of the elbow and forearm. It has been reported in swimmers, racquet players, weight lifters, and throwers who repeatedly pronate the elbow in full extension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/43\">",
"     43",
"    </a>",
"    ]. Conservative management, with avoidance of elbow flexion and pronation, may relieve symptoms, but surgical decompression of the biceps and brachialis fascia may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs and MRI may be necessary to evaluate the bones and soft tissues of the elbow of the athlete with elbow pain. Plain radiographs should be obtained in three views: anterior-posterior, lateral, and lateral oblique. The anterior-posterior view shows the epicondyles (medial and lateral) and the articular surfaces (radiocapitellar and ulnotrochlear). The lateral shows the relationship between the bones of the distal humerus and proximal forearm. The lateral oblique shows the radiocapitellar joint, medial epicondyle, radioulnar joint, and coronoid process. Comparison views do not increase diagnostic accuracy, but they may be helpful for patients who have inconclusive initial radiographic and clinical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous anatomic relationships should be evaluated on lateral elbow radiographs to avoid misdiagnosing subtle fractures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The line along the anterior humerus should intersect the middle one-third of the capitellum (anterior humeral line).",
"     </li>",
"     <li>",
"      The line of the long axis of the radius should extend through the middle of the capitellum (radiocapitellar line).",
"     </li>",
"     <li>",
"      The line drawn along the top of the coronoid process should barely cross the top of the capitellum and trochlea (coronoid line).",
"     </li>",
"     <li>",
"      The fat pad of the elbow usually sits along the anterior border of the coronoid fossa and is concave-shaped. The fat pad is displaced superiorly and ventrally and appears convex if a fracture (sail sign) is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI is an excellent tool in the evaluation of the soft tissue structures damaged in chronic overuse injuries. Muscles, tendons, ligaments, nerves, and articular cartilage as well as more subtle bone injuries such as occult fracture and osteochondritis dissecans are well-imaged using MRI.",
"   </p>",
"   <p>",
"    MRI with intra-articular contrast may be particularly useful in identifying partial and full-thickness tearing of the ulnar collateral ligament. MRI imaging of uninjured experienced high school pitchers demonstrated asymmetric thickening of the UCL (65 percent) and posteromedial subchondral sclerosis in the ulnotrochlear articulation (61 percent). This may represent morphologic changes from throwing or may demonstrate early degenerative changes in these young athletes. Clinical correlation is important when using imaging to make treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22937/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14649790\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elbow is made up of three interrelated joints (the radiocapitellar [radiohumeral], ulnohumeral, and radioulnar) and their stabilizing ligaments (",
"      <a class=\"graphic graphic_table graphicRef58982 \" href=\"UTD.htm?15/40/16011\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62086 graphicRef52653 \" href=\"UTD.htm?17/36/17990\">",
"       figure 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute elbow injuries can be caused by contact trauma, valgus trauma with the hand planted, a fall on an outstretched hand, or spontaneously. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic elbow injuries typically are caused by repetitive activity (eg, throwing a baseball). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination help to narrow the possible causes of an elbow injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for elbow pain in the young athlete is organized according to the location of pain (",
"      <a class=\"graphic graphic_table graphicRef68293 \" href=\"UTD.htm?38/53/39772\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs and MRI are useful adjuncts to the history and physical examination in athletes with elbow pain. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of insidious onset elbow pain is based on treating the underling etiology of overuse.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/1\">",
"      Amadio PC. Epidemiology of hand and wrist injuries in sports. Hand Clin 1990; 6:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/2\">",
"      Elgenmark, O. The normal development of the ossification centers during infancy and childhood. Acta Paediatr (Suppl) 1946; :33.",
"     </a>",
"    </li>",
"    <li>",
"     Tsai, AK, Ruiz, E. The elbow joint. In: Emergency Management of Skeletal Injuries, Ruiz, E, Cicero, J (Eds), Mosby-Year Book, St. Louis 1995. p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/4\">",
"      Posner MA. Compressive neuropathies of the median and radial nerves at the elbow. Clin Sports Med 1990; 9:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/5\">",
"      Rettig AC, Patel DV. Epidemiology of elbow, forearm, and wrist injuries in the athlete. Clin Sports Med 1995; 14:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/6\">",
"      Carlioz H, Abols Y. Posterior dislocation of the elbow in children. J Pediatr Orthop 1984; 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/7\">",
"      Rasool MN. Dislocations of the elbow in children. J Bone Joint Surg Br 2004; 86:1050.",
"     </a>",
"    </li>",
"    <li>",
"     Jenkins, DB. Hollinshead's Function Anatomy of the Limbs and Back, 6th, WB Saunders, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/9\">",
"      Copley LA, Dormans JP, Davidson RS. Vascular injuries and their sequelae in pediatric supracondylar humeral fractures: toward a goal of prevention. J Pediatr Orthop 1996; 16:99.",
"     </a>",
"    </li>",
"    <li>",
"     Elbow injuries. In: Sports Injuries: Diagnosis and Management, 2nd, Garrick, JG, Webb, DR (Eds), WB Saunders, Philadelphia 1999. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/11\">",
"      Kumar A, Ahmed M. Closed reduction of posterior dislocation of the elbow: a simple technique. J Orthop Trauma 1999; 13:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/12\">",
"      Hofammann KE 3rd, Moneim MS, Omer GE, Ball WS. Brachial artery disruption following closed posterior elbow dislocation in a child--assessment with intravenous digital angiography. A case report with review of the literature. Clin Orthop Relat Res 1984; :145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/13\">",
"      Alves EM, Macieira JC, Borba E, et al. Spontaneous tendon rupture in systemic lupus erythematosus: association with Jaccoud's arthropathy. Lupus 2010; 19:247.",
"     </a>",
"    </li>",
"    <li>",
"     Vanhees MK, Geurts G.F, Van Riet RP. Snapping triceps syndrome: a review of the literature. Shoulder &amp; Elbow 2010; 2: 30. doi: 10.1111/j.1758-5740.2009.00033.x file://onlinelibrary.wiley.com/doi/10.1111/j.1758-5740.2009.00033.x/full (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/15\">",
"      Gabel GT. Acute and chronic tendinopathies at the elbow. Curr Opin Rheumatol 1999; 11:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/16\">",
"      Sollender JL, Rayan GM, Barden GA. Triceps tendon rupture in weight lifters. J Shoulder Elbow Surg 1998; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/17\">",
"      Baker CL Jr, Jones GL. Arthroscopy of the elbow. Am J Sports Med 1999; 27:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/18\">",
"      Cabrera JM, McCue FC 3rd. Nonosseous athletic injuries of the elbow, forearm, and hand. Clin Sports Med 1986; 5:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/19\">",
"      Park MC, Ahmad CS. Dynamic contributions of the flexor-pronator mass to elbow valgus stability. J Bone Joint Surg Am 2004; 86-A:2268.",
"     </a>",
"    </li>",
"    <li>",
"     Jobe, FW, Fanton, GS. Nerve injuries. In: The Elbow and Its Disorders, Morrey, BF (Eds), WB Saunders, Philadelphia 1985. p.497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/21\">",
"      Walsh MT. Upper limb neural tension testing and mobilization. Fact, fiction, and a practical approach. J Hand Ther 2005; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/22\">",
"      Glousman RE. Ulnar nerve problems in the athlete's elbow. Clin Sports Med 1990; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/23\">",
"      Levine BP, Jones JA, Burton RI. Nerve entrapments of the upper extremity: A surgical perspective. Neurol Clin 1999; 17:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/24\">",
"      Pappas AM. Elbow problems associated with baseball during childhood and adolescence. Clin Orthop Relat Res 1982; :30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/25\">",
"      Olsen SJ 2nd, Fleisig GS, Dun S, et al. Risk factors for shoulder and elbow injuries in adolescent baseball pitchers. Am J Sports Med 2006; 34:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/26\">",
"      Fleisig GS, Andrews JR, Cutter GR, et al. Risk of serious injury for young baseball pitchers: a 10-year prospective study. Am J Sports Med 2011; 39:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/27\">",
"      Dun S, Loftice J, Fleisig GS, et al. A biomechanical comparison of youth baseball pitches: is the curveball potentially harmful? Am J Sports Med 2008; 36:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/28\">",
"      Fleisig GS, Kingsley DS, Loftice JW, et al. Kinetic comparison among the fastball, curveball, change-up, and slider in collegiate baseball pitchers. Am J Sports Med 2006; 34:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/29\">",
"      Lyman S, Fleisig GS, Andrews JR, Osinski ED. Effect of pitch type, pitch count, and pitching mechanics on risk of elbow and shoulder pain in youth baseball pitchers. Am J Sports Med 2002; 30:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/30\">",
"      Risk of injury from baseball and softball in children 5 to 14 years of age. American Academy of Pediatrics Committee on Sports Medicine. Pediatrics1994; 93:690.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.littleleague.org/media/pitch_count_08-25-06.asp (Accessed on June 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/32\">",
"      DaSilva MF, Williams JS, Fadale PD, et al. Pediatric throwing injuries about the elbow. Am J Orthop (Belle Mead NJ) 1998; 27:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/33\">",
"      Morrey BF, An KN. Articular and ligamentous contributions to the stability of the elbow joint. Am J Sports Med 1983; 11:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/34\">",
"      Jobe FW, Stark H, Lombardo SJ. Reconstruction of the ulnar collateral ligament in athletes. J Bone Joint Surg Am 1986; 68:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/35\">",
"      O'Driscoll SW, Lawton RL, Smith AM. The \"moving valgus stress test\" for medial collateral ligament tears of the elbow. Am J Sports Med 2005; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/36\">",
"      Schwartz ML, al-Zahrani S, Morwessel RM, Andrews JR. Ulnar collateral ligament injury in the throwing athlete: evaluation with saline-enhanced MR arthrography. Radiology 1995; 197:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/37\">",
"      Werner CO. Lateral elbow pain and posterior interosseous nerve entrapment. Acta Orthop Scand Suppl 1979; 174:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/38\">",
"      Plancher KD, Peterson RK, Steichen JB. Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Clin Sports Med 1996; 15:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/39\">",
"      Chan D, Aldridge MJ, Maffulli N, Davies AM. Chronic stress injuries of the elbow in young gymnasts. Br J Radiol 1991; 64:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/40\">",
"      Jackson DW, Silvino N, Reiman P. Osteochondritis in the female gymnast's elbow. Arthroscopy 1989; 5:129.",
"     </a>",
"    </li>",
"    <li>",
"     Bianco, AJ. Osteochondritis dissecans. In: The Elbow and Its Disorders, Morrey, BF (Eds), WB Saunders, Philadelphia 1985.",
"    </li>",
"    <li>",
"     Bennett, JB, Tullos, HS. Ligamentous and articular injuries in the athlete. In: The Elbow and Its Disorders, Morrey, BF (Eds), WB Saunders, Philadelphia 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/43\">",
"      Bassett FH 3rd, Nunley JA. Compression of the musculocutaneous nerve at the elbow. J Bone Joint Surg Am 1982; 64:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22937/abstract/44\">",
"      Hurd WJ, Eby S, Kaufman KR, Murthy NS. Magnetic resonance imaging of the throwing elbow in the uninjured, high school-aged baseball pitcher. Am J Sports Med 2011; 39:722.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6524 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-063D528ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22937=[""].join("\n");
var outline_f22_25_22937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14649790\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SKELETAL MATURITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Additional questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurovascular examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Provocative testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anterior elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Anterior capsule strain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Median nerve compression syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Posterior elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Posterior elbow dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Olecranon bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Triceps tendinitis or rupture (snapping tendonitis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Valgus extension overload/olecranon impingement syndrome (VEO/OIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Medial elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Medial epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Ulnar neuritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Little league elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Medial epicondyle apophysitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Medial epicondyle avulsion fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Ulnar collateral ligament tears",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Lateral elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Lateral epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Radial nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Radiocapitellar joint injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Musculocutaneous nerve entrapment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14649790\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6524|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/41/2704\" title=\"diagnostic image 1\">",
"      Osteochondritis dissecans of the elbow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6524|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/40/17025\" title=\"figure 1A\">",
"      Lateral elbow ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/57/40848\" title=\"figure 1B\">",
"      Medial elbow ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/40/32390\" title=\"figure 2\">",
"      Forearm extensors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/29/28118\" title=\"figure 3\">",
"      Forearm pronators supinators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/53/43858\" title=\"figure 4A\">",
"      Elbow ossification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/1/33809\" title=\"figure 4B\">",
"      Elbow fusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6524|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/33/26142\" title=\"picture 1\">",
"      OK sign to assess median nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/23/28019\" title=\"picture 2\">",
"      Resisted wrist flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/46/7904\" title=\"picture 3\">",
"      Tinel sign for ulnar neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/20/1346\" title=\"picture 4\">",
"      Resisted wrist extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/19/18751\" title=\"picture 5\">",
"      Long finger extension test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/40/16011\" title=\"table 1\">",
"      Elbow ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/11/24763\" title=\"table 2\">",
"      Elbow sensation strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/19/12604\" title=\"table 3\">",
"      Skeletal maturity timeframe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/4/8267\" title=\"table 4\">",
"      DDx medial elbow injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43115\" title=\"table 5A\">",
"      Range of motion elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/11/28859\" title=\"table 5B\">",
"      Strength exam elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/4/2125\" title=\"table 6\">",
"      Provocative elbow testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/53/39772\" title=\"table 7\">",
"      DDx Elbow pain children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=related_link\">",
"      Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=related_link\">",
"      Management of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=related_link\">",
"      Use of androgens and other hormones to enhance athletic performance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_25_22938="Cytogenetics in acute lymphoblastic leukemia";
var content_f22_25_22938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytogenetics in acute lymphoblastic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Yanming Zhang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Michelle M Le Beau, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/25/22938/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/25/22938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful prognostic indicators in acute lymphoblastic leukemia (ALL) are age, white blood cell count, immunophenotype, minimal residual disease detection, and karyotype. A number of recurring cytogenetic abnormalities are associated with distinct immunologic phenotypes of ALL and characteristic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These abnormalities will be reviewed here. An overview of cytogenetic analysis in hematologic malignancies, including definitions, methods of detection, and the genetic consequences of chromosomal translocations, is presented separately, as is the use of minimal residual disease assessment in patients with ALL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     B CELL ACUTE LYMPHOBLASTIC LEUKEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cytogenetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic analysis and molecular cytogenetic studies, such as fluorescence in situ hybridization (FISH), reveal recurring chromosome abnormalities in approximately 80 percent of ALL, including numerical and structural changes, such as translocations, inversions, or deletions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/1,2,5-7\">",
"     1,2,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are substantial differences between children and adults with ALL in the frequencies of some recurring abnormalities, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The t(9;22) is observed in about 2 to 5 percent of children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/8-10\">",
"       8-10",
"      </a>",
"      ] compared with about 30 percent of adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/5,7,11\">",
"       5,7,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The t(12;21), which is detectable only by FISH or polymerase chain reaction (PCR) analysis, is observed in about 25 percent of children with B-lineage leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/6,12\">",
"       6,12",
"      </a>",
"      ], compared with about 3 percent of adults.",
"     </li>",
"     <li>",
"      A hyperdiploid karyotype is found in 30 to 40 percent of children compared with 2 to 10 percent of adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/6,10\">",
"       6,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The t(4;11) is present in up to 60 percent of infants younger than 12 months, but is rarely observed in adult ALL patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/6,13\">",
"       6,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As will be described below, certain translocations, such as t(4;11) and t(9;22), are associated with treatment failure even when using intensive chemotherapy; in comparison, the t(12;21), t(1;19), and hyperdiploidy (50 to 60 chromosomes) are associated with a more favorable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/6,8,9,11-15\">",
"     6,8,9,11-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     8;14 translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reciprocal translocation involving the long arms of chromosomes 8 and 14, designated t(8;14)(q24.1;q32), is present in a high proportion of Burkitt cell tumors of both African and non-African origin. The same translocation occurs in patients with ALL with FAB-L3-type leukemia cells, suggesting that Burkitt lymphoma and most B cell ALL of the L3 type are different manifestations of the same disease. Variant translocations have been described in some patients with Burkitt lymphoma and B cell ALL, including t(2;8)(p12;q24.1) and t(8;22)(q24.1;q11.2). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathobiology of Burkitt lymphoma\", section on 'Chromosomal translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 1522 adult patients with ALL, the t(8;14) and its variants were detected in 16 (1 percent) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/10\">",
"     10",
"    </a>",
"    ]. Eight of these patients had a mature B cell immunophenotype, whereas the remaining cases showed a common or pre-B (CD10-positive) phenotype. These patients had a high incidence of central nervous system involvement at diagnosis and a poorer prognosis than any other group of patients classified by chromosomal abnormalities. In a series of 21 adults with a t(8;14), all of whom had B cell ALL; the complete remission rate was 62 percent, but the median event-free survival was only two months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     4;11 translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Translocations involving 11q23 are observed in 5 to 7 percent of patients with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/2,4,7,10\">",
"     2,4,7,10",
"    </a>",
"    ]. The most common is t(4;11)(q21;q23); the t(11;19)(q23;p13.3) is second in frequency. However, about 50 percent of patients with the latter rearrangement have AML, usually acute monoblastic leukemia (AML-M5). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the t(4;11) and ALL have a number of characteristic clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/2,4,12,13,15-20\">",
"     2,4,12,13,15-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High leukocyte counts (median",
"      <span class=\"nowrap\">",
"       183,000/&micro;L)",
"      </span>",
"     </li>",
"     <li>",
"      L1 or L2 morphology",
"     </li>",
"     <li>",
"      An immature (progenitor B cell) immunophenotype (CD10-, CD19+, HLA-DR+)",
"     </li>",
"     <li>",
"      B cell lineage",
"     </li>",
"     <li>",
"      Frequent co-expression of myeloid antigens (CD15+, CDw65+)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases of t(4;11) acute leukemia, the blasts are lymphoid in appearance and are classified by light microscopy as L1 or L2 according to the FAB system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/2,4,6\">",
"     2,4,6",
"    </a>",
"    ]. A notable finding is that the leukemia cells in about 50 percent of patients with the t(4;11) express myeloid enzymes, such as myeloperoxidase or nonspecific esterase (a granulocyte-monocyte marker) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/13,21\">",
"     13,21",
"    </a>",
"    ]. Thus, occasional blasts appear monocytic and, in some patients, lymphoid and monocytoid blasts occur in approximately equal proportion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/13\">",
"     13",
"    </a>",
"    ]. These leukemic cells are generally terminal deoxynucleotidyl transferase (Tdt) positive and usually express pan-B cell antigens; in comparison, T cell markers are absent.",
"   </p>",
"   <p>",
"    The t(4;11) fuses the MLL gene",
"    <span class=\"nowrap\">",
"     (myeloid/lymphoid,",
"    </span>",
"    or mixed-lineage, leukemia) on chromosome 11 band q23 to the AFF1 (AF4) gene on chromosome 4 band q21, forming an",
"    <span class=\"nowrap\">",
"     MLL/AFF1",
"    </span>",
"    fusion gene, which is transcribed into a hybrid mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/22\">",
"     22",
"    </a>",
"    ]. Reverse transcriptase-polymerase chain reaction (RT-PCR) techniques have been developed for this transcript, which have been used for monitoring of residual disease in this ALL variant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ALL with a t(4;11) has a poor prognosis in both adults and children. Typical findings include a remission rate of 75 percent, but a median event-free survival of only seven months in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/2,7,13,23\">",
"     2,7,13,23",
"    </a>",
"    ], and a complete remission rate of 88 percent but a median survival of 10 months in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,12,16\">",
"     4,12,16",
"    </a>",
"    ]. In a group of 35 infant ALL patients with t(4;11), the five-year event-free survival was only 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351299836\">",
"    <span class=\"h4\">",
"     t(11q23) and&nbsp;ALL in infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority (60 to 80 percent) of infants with ALL have translocations involving 11q23 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,18-20,24,25\">",
"     4,18-20,24,25",
"    </a>",
"    ]. These translocations involve the MLL gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/19,20,24,26,27\">",
"     19,20,24,26,27",
"    </a>",
"    ]. The MLL protein is a histone methyltransferase that assembles in protein complexes that regulate gene transcription via chromatin remodeling. Target genes of the MLL transcriptional regulatory complexes include the HOX genes and the IKZF1 (IKAROS) gene, which have a critical role in development as well as hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/27\">",
"     27",
"    </a>",
"    ]. IKZF1 is a DNA-binding protein that is required for normal lymphocyte development. Mutant mice that express only dominant-negative IKZF1 isoforms develop ALL at three to six months of age; similar isoforms have been identified in infants with ALL and MLL translocations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Gene expression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Leukemias with MLL translocations have a characteristic, highly distinct gene expression profile, suggesting that they constitute a distinct disease, characterized by a high rate of early treatment failure and a very poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/19,20,29,30\">",
"     19,20,29,30",
"    </a>",
"    ]. In one series, for example, the estimated event-free survival in infants with ALL and an MLL rearrangement was 19 percent at three years compared with 46 percent for patients with germline MLL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/19\">",
"     19",
"    </a>",
"    ]. In another series of 1725 childhood ALL patients, the event-free and overall survival rates at five years were 50 and 60 percent, respectively, compared with 89 and 96 percent of patients with t(12;21) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/12\">",
"     12",
"    </a>",
"    ]. Among infants with MLL rearrangements, the t(4;11) may confer a particularly poor prognosis; as a result, intensified therapy, including transplantation, may be preferred in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,12,20\">",
"     4,12,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     9;22 translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(9;22)(q34;q11.2) resulting in the Philadelphia (Ph) chromosome is observed in about 5 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] compared with about 30 percent of adults overall [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,5,7,11\">",
"     4,5,7,11",
"    </a>",
"    ] and 50 percent of adults with B-lineage ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/11\">",
"     11",
"    </a>",
"    ]. The normal primitive stem cell, rather than a committed lymphoid progenitor, appears to be the target for leukemic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/31\">",
"     31",
"    </a>",
"    ]. The fusion product of the Ph chromosome (the",
"    <span class=\"nowrap\">",
"     BCR/ABL1",
"    </span>",
"    protein), which is also seen in chronic myeloid leukemia (CML), is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Ph chromosome is the most frequent rearrangement in adult ALL. In one series of 141 consecutive adults with ALL, for example, 36 (26 percent) had a t(9;22); all of these occurred among the 109 patients with precursor B ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/32\">",
"     32",
"    </a>",
"    ]. However, some patients have had both B cell and myeloid markers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/8,11,33\">",
"     8,11,33",
"    </a>",
"    ]. Because of the high frequency of the",
"    <span class=\"nowrap\">",
"     BCR/ABL1",
"    </span>",
"    rearrangement and its dire clinical consequences, molecular studies using RT-PCR should be routinely performed at diagnosis when clinical suspicion is high and cytogenetic analysis is nondiagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large series of 1522 adult ALL patients from the UK MRC and ECOG clinical trial, 267 (19 percent) patients had the t(9;22) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/10\">",
"     10",
"    </a>",
"    ]. In this study, as well as in one reported by CALGB [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/35\">",
"     35",
"    </a>",
"    ], approximately 60 to 70 percent of patients had abnormalities in addition to the Ph chromosome; gain of a Ph chromosome, monosomy 7, +8, +X, and del(9p) are among the commonly associated secondary abnormalities. However, the survival significance of these secondary chromosome abnormalities is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/9,10,35\">",
"     9,10,35",
"    </a>",
"    ]. Interestingly, these abnormalities differ from those that evolve during the accelerated and blast phases of CML. Another difference from CML is that approximately 70 percent of patients with Ph chromosome positive ALL have a chromosomally normal cell line in the bone marrow at diagnosis, a rare finding in untreated CML.",
"   </p>",
"   <p>",
"    Molecular studies of Ph chromosome positive ALL have revealed two distinct subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In approximately 30 to 50 percent of adults, the molecular rearrangement is identical to that seen in CML. The breaks occur within the ABL1 gene and within the major bcr region (called M-bcr) of the BCR gene, producing a chimeric gene that encodes for a 210 kilodalton fusion protein. Many of these patients have persistence of metaphase cells with the Ph chromosome after chemotherapy-induced hematologic remissions. They also have the Ph chromosome in myeloid cells and in myeloid colonies grown in vitro, suggesting that they represent cases of CML presenting in lymphoid blast crisis after an unrecognized chronic phase.",
"     </li>",
"     <li>",
"      In the remaining patients, the breakpoint occurs upstream of bcr but still within the BCR gene (called m-bcr), giving rise to smaller fusion proteins (185 to 190 kilodaltons) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. Most of these patients lack the additional cytogenetic abnormalities typical of CML blast crisis, do not have the Ph chromosome in myeloid cells and colonies, and become Ph chromosome negative in hematologic remission. These observations suggest that the Ph translocation occurred in a cell that is more restricted in its differentiation, perhaps a committed B-lymphoid progenitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the 210 and 185 kilodalton fusion proteins are involved in constitutive signaling via the RAS pathway of signal transduction and promote leukemogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In a mouse model, animals transplanted with cells transfected with p185",
"    <span class=\"nowrap\">",
"     BCR/ABL1",
"    </span>",
"    develop tumors more rapidly than those transplanted with p210",
"    <span class=\"nowrap\">",
"     BCR/ABL1",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/41\">",
"     41",
"    </a>",
"    ]. This could explain why patients with Ph chromosome positive ALL are biologically and clinically different from those with CML even though both disorders have the same chromosomal abnormality. The observation that patients in whom the Ph chromosome is restricted to lymphoblasts, which is more common with the m-bcr breakpoint, have shorter survivals than those with multilineage involvement (median 8 versus 47 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] is compatible with the mouse studies showing more aggressive disease with p185",
"    <span class=\"nowrap\">",
"     BCR/ABL1.",
"    </span>",
"   </p>",
"   <p>",
"    Ph chromosome positivity is a poor prognostic sign in ALL. Early chemotherapy trials reported no survivors at five years in adults with this abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The initial response is better with more intensive regimens, but the likelihood of remaining in remission is still much lower than in those without this translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/7\">",
"     7",
"    </a>",
"    ]. In a prospective study conducted by the Cancer and Leukemia Group B (CALGB), patients with ALL who were Ph chromosome positive, when compared with those who were Ph chromosome negative, had a similar complete remission rate (71 versus 77 percent), but a shorter median duration of remission (10 versus 18 months) and survival (11 versus 22 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/11\">",
"     11",
"    </a>",
"    ]. In a later review of clinical trials from CALGB, the likelihood of remaining in remission was much lower in patients who were Ph chromosome positive . In the",
"    <span class=\"nowrap\">",
"     MRC/ECOG",
"    </span>",
"    clinical trial, the five-year event-free and overall survival rates in Ph positive ALL patients were 16 and 22 percent, respectively, in comparison with 36 and 41 percent in those without the t(9;22) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tyrosine kinase (TK) inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) that target the BCR-ABL1 fusion protein have been used in combination with chemotherapy in the initial treatment of Ph positive ALL. The addition of a TK inhibitor results in significantly higher rates of complete remission and overall survival. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link&amp;anchor=H19#H19\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Philadelphia chromosome positive ALL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     1;19 translocation in pre-B cell ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-B cell ALL is a distinct subtype of ALL that can be distinguished from null-cell and common B cell ALL by the presence of cytoplasmic immunoglobulin mu-chain (C&micro;) expression. The pre-B leukemias have rearrangements of the immunoglobulin heavy chain genes and occasionally of the light chain genes. The t(1;19) occurs in approximately 30 percent of patients with pre-B cell childhood ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/47\">",
"     47",
"    </a>",
"    ]. Although most common in pre-B cell ALL, the t(1;19) can also occur in other B lineage cells including precursor B cell, null cell, and mature B cell ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/32,47\">",
"     32,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with pre-B ALL and this translocation tend to have a white blood cell count of",
"    <span class=\"nowrap\">",
"     &gt;20,000/microL",
"    </span>",
"    and a characteristic surface antigen profile that is CD19+, CD10+ (CALLA+), CD22+, CD34-, and",
"    <span class=\"nowrap\">",
"     CD20+/-",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In comparison, the t(1;19) is much less common in ALL in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/7,32\">",
"     7,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The t(1;19) occurs in two forms: a reciprocal translocation, t(1;19)(q23;p13.3) or, more often, an unbalanced form characterized by two normal chromosome 1 and 19 homologs, and a rearranged chromosome 19, der(19)t(1;19)(q23;p13.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/49\">",
"     49",
"    </a>",
"    ]. The presenting clinical and laboratory features and event-free survival appear to be the same for these two subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The t(1;19) involves the TCF3 (E2A) gene at 19p13.3; this gene encodes two transcription factors (E12 and E47) that bind to enhancer elements in the IGK gene and to the regulatory elements of other genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In the translocation, the TCF3 gene is juxtaposed with PBX1, a homeobox (HOX) gene on chromosome 1. HOX genes encode DNA-binding transcription factors that regulate developmental processes and hematopoiesis.",
"    <span class=\"nowrap\">",
"     TCF3/PBX1",
"    </span>",
"    fusion mRNAs are formed and code for chimeric proteins that consist of the transcriptional activating domain of",
"    <span class=\"nowrap\">",
"     E12/E47",
"    </span>",
"    and the DNA-binding and protein dimerization domains of PBX1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. TCF3 is expressed in all tissues; the normal PBX1 gene is expressed in many fetal and adult tissues, but not in lymphoid cells.",
"   </p>",
"   <p>",
"    How the",
"    <span class=\"nowrap\">",
"     TCF3/PBX1",
"    </span>",
"    fusion protein might promote leukemogenesis is not well understood. The following possible mechanisms for transcriptional activation have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fusion protein may directly activate gene transcription of PBX1-HOX-complex target genes.",
"     </li>",
"     <li>",
"      The fusion protein may bind DNA cooperatively with a specific HOX protein; the potent transactivation domain of TCF3 may then activate gene transcription.",
"     </li>",
"     <li>",
"      The PBX1-HOX complexes formed with other ubiquitously expressed PBX family members may normally inhibit transcription; in comparison,",
"      <span class=\"nowrap\">",
"       TCF3/PBX1/HOX",
"      </span>",
"      complexes may induce the transcription of genes that are normally repressed in lymphoid cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With each of these scenarios, the fusion protein may lead to the transactivation of a number of genes that are not normally expressed in lymphoid tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. As an example, a novel WNT gene is normally expressed in peripheral lymphoid organs but not in bone marrow. However, high levels of WNT-16 transcripts are present in bone marrow and cell lines from patients with pre-B ALL who have the",
"    <span class=\"nowrap\">",
"     TCF3/PBX1",
"    </span>",
"    fusion gene; furthermore, expression of WNT-16 is reduced by inhibition of",
"    <span class=\"nowrap\">",
"     TCF3/PBX1",
"    </span>",
"    expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, patients with the t(1;19) typically had early treatment failure, suggesting that this translocation may distinguish a subgroup of patients who have a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/49,50,55\">",
"     49,50,55",
"    </a>",
"    ]. In one large study, the adverse outcome of patients with the t(1;19) remained significant even after adjustment for recognized adverse clinical features, indicating that it is an independent risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/50\">",
"     50",
"    </a>",
"    ]. However, studies have shown that this adverse prognosis can be overcome by more intensive chemotherapy. In the",
"    <span class=\"nowrap\">",
"     MRC/ECOG",
"    </span>",
"    study, the event-free and overall survival rates at five-years were 80 and 84 percent, respectively, which is comparable to those (84 and 93 percent) with a hyperdiploid clone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/12\">",
"     12",
"    </a>",
"    ]. In fact, t(1;19), t(12;21) and hyperdiploidy are all associated with a favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     12;21 translocation in precursor B ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A t(12;21)(p12;q22) is the most common genetic lesion in childhood ALL, occurring in 15 to 25 percent of children with B-lineage disease, specifically precursor B ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Most affected children are between the ages of 1 and 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/56,59,60\">",
"     56,59,60",
"    </a>",
"    ]. This translocation is less common in adults, accounting for about 3 to 4 percent of patients with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], and is not seen in T cell ALL.",
"   </p>",
"   <p>",
"    The t(12;21) is not easily detected by cytogenetic analysis because of the similarity in size and banding patterns of 12p and 21q [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/56\">",
"     56",
"    </a>",
"    ]. As a result, RT-PCR or FISH analysis is required to detect this rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The t(12;21) fuses the ETV6 (TEL) gene at 12p12 with the",
"    <span class=\"nowrap\">",
"     RUNX1/AML1",
"    </span>",
"    gene at 21q22, resulting in the production of a fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RUNX1 protein (also known as core binding factor alpha-2, CBFA2) is a member of a family of transcription factors with homology to the pair-rule Drosophila gene, runt. RUNX1 heterodimerizes with another protein, core binding factor beta (CBFB, also known as PEBP2 beta), to form a transcription factor.",
"     </li>",
"     <li>",
"      The ETV6 protein functions as a transcriptional repressor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/63\">",
"       63",
"      </a>",
"      ]. It contains two domains: a helix-loop-helix (HLH) protein dimerization domain and an ETS DNA binding domain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The t(12;21) results in fusion of the 5' HLH domain of ETV6 with the 3' DNA-binding and transactivation domain of RUNX1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/62\">",
"     62",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     ETV6/RUNX1",
"    </span>",
"    inhibits transactivation of gene expression by the normal RUNX1 protein, an effect that requires the HLH domain of ETV6. In many patients with ALL and the t(12;21), the ETV6 allele on the other chromosome 12 homolog is deleted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/64\">",
"     64",
"    </a>",
"    ], which has no effect on the favorable prognostic significance. Alterations of both ETV6 alleles in leukemic cells suggest that ETV6 may be a tumor suppressor gene.",
"   </p>",
"   <p>",
"    The ETV6 gene is also involved in several other recurring translocations in the leukemias and myeloproliferative disorders, including the t(5;12)(q33;p12) in chronic myelomonocytic leukemia. In this translocation, ETV6 is fused to the platelet-derived growth factor receptor (PDGFR)-beta gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/65\">",
"     65",
"    </a>",
"    ]. Direct evidence supporting a pathogenetic role for this fusion protein comes from a transgenic mouse model in which expression of the ETV6-PDGFRB fusion mRNA produces a myeloproliferative disorder that shares features with chronic myelomonocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ETV6/RUNX1",
"    </span>",
"    fusion gene can be detected in B lineage progenitor cells during normal prenatal hematopoiesis in approximately 1 percent of developing fetuses, but only progresses to frank ALL in 1 percent of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/67\">",
"     67",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     ETV6/RUNX1",
"    </span>",
"    appears to induce a preleukemic stage, but additional cooperating genetic mutations are required for the conversion into acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ALL and the t(12;21) generally have a favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,12,56-59\">",
"     4,12,56-59",
"    </a>",
"    ]. One series, for example, evaluated 188 patients with precursor B ALL, 48 of whom (26 percent) had a rearrangement of the ETV6 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients with the ETV6 rearrangement had a much higher five-year event-free survival than those without the rearrangement (91 versus 65 percent). In the",
"    <span class=\"nowrap\">",
"     MRC/ECOG",
"    </span>",
"    study, the event-free and overall survival rates at five years of 368 childhood ALL patients with the t(12;21) were 89 and 96 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/12\">",
"     12",
"    </a>",
"    ]. In another report, none of 22 patients with the",
"    <span class=\"nowrap\">",
"     TEL/RUNX1",
"    </span>",
"    fusion relapsed compared with 16 of 54 (30 percent) without the",
"    <span class=\"nowrap\">",
"     ETV6/RUNX1",
"    </span>",
"    fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these patients would fall into a high-risk group using standard risk factors. Thus, the presence of t(12;21) may identify patients within the \"high-risk\" group who would benefit from less toxic and less intensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/58\">",
"     58",
"    </a>",
"    ]. However, within the group of children with ALL and t(12;21), those with the CpG island methylator phenotype (CIMP) may be at higher risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hyperdiploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with ALL have a gain of many chromosomes in the leukemic cells with relatively few structural abnormalities. Two subgroups have been described: a group with 1 to 4 extra chromosomes (total 47 to 50) and a more common group that usually has 51 to 60 chromosomes but may have up to 65 chromosomes. Chromosome 21 is gained most frequently (100 percent of cases), and multiple additional copies of this chromosome are often seen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,71-73\">",
"     4,71-73",
"    </a>",
"    ]. Other frequent additional chromosomes include the X chromosome, and chromosomes 4, 6, 10, 14, 17, and 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structural rearrangements occur in the leukemic cells in as many of 25 percent of patients with hyperdiploid ALL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/73\">",
"     73",
"    </a>",
"    ]. The most common are duplication of 1q (14 percent) and an isochromosome of 17q (5 percent). Chromosomal translocations occur in approximately 5 to 10 percent, including t(9;22) and t(1;19).",
"   </p>",
"   <p>",
"    Patients who have hyperdiploidy with more than 50 chromosomes often have all of the clinical features that indicate a good prognosis. These include age between one and nine years, low white blood cell count (median",
"    <span class=\"nowrap\">",
"     6700/microL),",
"    </span>",
"    and favorable immunophenotype (early pre-B or pre-B) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. It has been suggested that this is not a uniform group, as the prognosis of children with 51 to 55 chromosomes may differ from those with 56 to 65 chromosomes. In a series of 168 patients, the 105 patients with 51 to 55 chromosomes had a significantly lower event-free survival at five years (72 versus 86 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/73\">",
"     73",
"    </a>",
"    ]. Adverse prognosis features within the 51 to 55 chromosome group included a higher frequency of isochromosome 17 and a white blood cell count above",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    Structural abnormalities did not appear to influence event-free survival except for a poor prognosis associated with the t(9;22).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypodiploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 6 percent of ALL patients, independent of age, have clonal loss of various chromosomes, resulting in a hypodiploid clone with fewer than 46 chromosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/74\">",
"     74",
"    </a>",
"    ]. Three distinct subgroups of hypodiploidy in ALL have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Near-haploidy (23 to 29 chromosomes)",
"     </li>",
"     <li>",
"      Low hypodiploidy (33 to 39 chromosomes)",
"     </li>",
"     <li>",
"      High hypodiploidy (42 to 45 chromosomes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Near-haploidy is exclusively observed in children (median age of 7 years), whereas low hypodiploidy is noted in relatively older patients (median age of 15 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/74\">",
"     74",
"    </a>",
"    ]. In cytogenetic analysis, the near-haploid clone is often accompanied by a doubling of the chromosome complement (tetraploidization) resulting in a hyperdiploid population with a gain of two copies of certain chromosomes, which is distinguishable from the more common hyperdiploid clone with a single gain of certain chromosomes. More detailed genetic studies in 124 cases of hypodiploid ALL, including whole-genome and exome sequencing of 40 cases, identified differences in the genetic alterations among cases with near-haploidy and low hypodiploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/75\">",
"     75",
"    </a>",
"    ]. Near-haploid cases demonstrated a higher frequency of alterations involving tyrosine kinase signaling and Ras signaling (71 percent) and IKZF3 (13 percent), whereas low hypodiploidy cases demonstrated alterations in TP53 (91 percent), IKZF2 (53 percent), and RB1 (41 percent). Both groups demonstrated activation of Ras signalling and PI3K signaling pathways.",
"   </p>",
"   <p>",
"    ALL patients with hypodiploid clones generally have a poor prognosis, especially patients with near-haploid and low-hypodiploid clones. As an example, one study showed that the three-year event-free-survival of children with near-haploid and low-hypodiploid clones was 29 percent, whereas it was 66 percent for those with high hypodiploid clones (42 to 45 chromosomes) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/74\">",
"     74",
"    </a>",
"    ]. In this regard, it is critical to avoid confusing the doubled (tetraploid) populations of a hypodiploid clone with a true hyperdiploid population, as the prognosis is considerably different between these cytogenetic groups. DNA index analysis and FISH tests can help clarify such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     9p abnormalities in ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of childhood and adult ALL cases show a deletion of the short arm of chromosome 9. It can occur as a single abnormality in both children and adult patients. However, it often exists as a part of a complex clone with other numerical and structural abnormalities, in particular with a del(12p) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/76\">",
"     76",
"    </a>",
"    ]. Loss of material from 9p can be in various forms, such as del(9p), add(9p), der(9)t(V;9)(V;p), an isochromosome of 9q, or a dicentric chromosome with 9q.",
"   </p>",
"   <p>",
"    In one study, microarray analysis and genomic DNA sequencing identified a mono-allelic deletion of the PAX5 gene at 9p13.2 in 28 percent of ALL patients with a cryptic or a large deletion involving 9p [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/77\">",
"     77",
"    </a>",
"    ]. Deletion or mutation of the PAX5 gene results in reduced level of the PAX5 protein or the generation of hypomorphic alleles, thereby leading primarily to loss of function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatically acquired mutations in the Janus kinase (JAK2) gene on chromosome band 9p24 has been reported in 18 percent of patients with Down syndrome associated ALL, but is not commonly found in ALL patients without Down syndrome or in patients with Down syndrome associated acute megakaryoblastic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. This JAK2 mutation (R683) differs from the V617 mutation commonly seen in myeloproliferative neoplasms.",
"   </p>",
"   <p>",
"    Activating mutations of JAK2 may cooperate with another genetic lesion, a P2RY8-CRLF2 fusion, to contribute to leukemogenesis in B-progenitor ALL via the induction of constitutive Jak-Stat signaling and cytokine-independent growth. A recurring interstitial deletion of the pseudoautosomal region 1 of the X and Y chromosomes in progenitor B ALL juxtaposes the first, noncoding exon of P2RY8 with the coding region of CRLF2. The P2RY8-CRLF2 fusion occurs in 7 percent of B-progenitor ALL and 53 percent of patients with Down syndrome associated ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletion of 9p is an unfavorable risk factor associated with a high rate of relapse in precursor-B ALL in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/82\">",
"     82",
"    </a>",
"    ]. This is more pronounced in standard-risk patients defined as those one to nine years old with WBC count below",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 381 adult patients with precursor-B ALL, 8 percent had abnormalities in 9p [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/83\">",
"     83",
"    </a>",
"    ]. This group showed an overall survival that was significantly shorter than those with normal karyotypes, and similar to those with poor prognosis",
"    <span class=\"nowrap\">",
"     t(9;22)/BCR-ABL1",
"    </span>",
"    positive ALL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gene expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures of gene expression through gene expression profiles, expression analyses of individual genes (eg, IKZF1), and analysis of the epigenetic regulation of microRNAs (eg, methylation) appear to have prognostic value in patients with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/77,84-90\">",
"     77,84-90",
"    </a>",
"    ]; the clinical value of such studies is yet to be determined.",
"   </p>",
"   <p>",
"    Genomewide analyses of patients with ALL have identified deletions or loss of function mutations in genes that regulate lymphocyte development. As an example, one study evaluated single-nucleotide polymorphism arrays and genomic DNA sequencing in 242 pediatric patients with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/77\">",
"     77",
"    </a>",
"    ]. Forty percent of B-ALL cases were found to have deletion, amplification, point mutations, or structural rearrangement in genes regulating B lymphocyte development and differentiation. Of these, the two most frequent abnormalities were in PAX5 and IKZF1 (in approximately 32 and 28 percent or patients, respectively). (See",
"    <a class=\"local\" href=\"#H11\">",
"     '9p abnormalities in ALL'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    IKZF1 (IKAROS family zinc finger 1) located at 7p13 encodes the IKAROS zinc finger binding protein that is required for normal lymphoid development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/84\">",
"     84",
"    </a>",
"    ]. Splicing abnormalities of IKZF1 may be found in over 80 percent of patients with Philadelphia chromosome (Ph) positive ALL and certain isoforms may be associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. However, abnormalities of IKZF1 may be associated with a poor outcome independent of Ph status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/91\">",
"     91",
"    </a>",
"    ]. As an example, a DNA copy number analysis of 221 patients with Ph negative high risk B-ALL (training cohort) and 258 unselected patients with B-ALL (validation cohort) reported that patients with IKZF1 deletions had an increased frequency of relapse at 5 and 10 years and resistance to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/87\">",
"     87",
"    </a>",
"    ]. The poor prognosis associated with IKZF1 abnormalities was independent of Ph status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cell cycle regulatory genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in cell cycle regulatory genes are also present in ALL and may affect prognosis.",
"   </p>",
"   <p>",
"    In a series of 42 patients, 85 percent had such abnormalities with 13 percent having more than one [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/92\">",
"     92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      RB1-Retinoblastoma gene (51 percent)",
"     </li>",
"     <li>",
"      p16 gene (also called CDKN2A and multiple tumor suppressor 1) (41 percent)",
"     </li>",
"     <li>",
"      TP53 gene (26 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with more than one abnormality had a significantly shorter median survival (8 versus 25 months).",
"   </p>",
"   <p>",
"    In a second study in 70 patients, abnormalities (deletion, methylation) of the CDKN2B (p15) and CDKN2A (p16) genes were noted in 69 and 39 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/93\">",
"     93",
"    </a>",
"    ]. On multivariate analysis, absence of CDKN2B gene alterations was a favorable prognostic factor for longer disease-free survival.",
"   </p>",
"   <p>",
"    In a third study in 251 consecutive patients with ALL, the hypermethylation profile of cancer-related genes was an independent prognostic factor in predicting disease-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     T CELL ACUTE LYMPHOBLASTIC LEUKEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with T cell ALL are most often young males. They have a number of unfavorable presenting characteristics including a mediastinal tumor mass, high white blood cell count",
"    <span class=\"nowrap\">",
"     (&ge;50,000/microL),",
"    </span>",
"    and leukemic cells in the cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. These characteristics are also associated with T cell lymphoblastic lymphoma, a related T cell malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children with T-ALL, approximately 60 percent have an abnormal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/96\">",
"     96",
"    </a>",
"    ]. These patients have a distinct pattern of recurring karyotypic abnormalities involving both T cell receptor (TCR) and non-TCR gene loci [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/95,96,98-100\">",
"     95,96,98-100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     TCR gene rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common rearrangements involve the proximal bands of chromosome 14 (14q11.2) and two regions of chromosome 7 (7q34 and 7p14). These rearrangements occur at the locations of the T cell receptor (TCR) genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TCR",
"      <span class=\"nowrap\">",
"       alpha/delta",
"      </span>",
"      chain at 14q11.2",
"      <span class=\"nowrap\">",
"       (TRA@/TRD@)",
"      </span>",
"     </li>",
"     <li>",
"      TCR beta chain at 7q34 (TRB@)",
"     </li>",
"     <li>",
"      TCR gamma chain at 7p14 (TRG@)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With few exceptions, the involved gene on the partner chromosome encodes a cell cycle inhibitor or a transcription factor whose expression is deregulated or activated as a result of the rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/95,99,103\">",
"     95,99,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oncogenes typically involved in TCR gene rearrangements may be overexpressed by other mechanisms. As an example, two children with X-linked severe combined immunodeficiency who received gene therapy using a provirus developed a T cell acute leukemia-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/100\">",
"     100",
"    </a>",
"    ]. The provirus was integrated within the LMO2 gene locus (11p13), which encodes one of the oncogenes frequently involved in TCR gene rearrangements (eg, t(11;14), t(7;11)). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Non-TCR loci",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of karyotypic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mutational abnormalities can occur in T cell ALL that do not involve the T cell receptor (TCR) loci. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      del(6q)",
"     </li>",
"     <li>",
"      t(11q23) (MLL gene)",
"     </li>",
"     <li>",
"      t(14q32)",
"     </li>",
"     <li>",
"      Trisomy 8",
"     </li>",
"     <li>",
"      t(10;11) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/104\">",
"       104",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gain-of-function NOTCH1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/105-108\">",
"       105-108",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      JAK1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/109\">",
"       109",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Overexpression of the TLX1 (HOX11) oncogenic transcription factor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/110-112\">",
"       110-112",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NOTCH1 signalling is necessary for commitment to the T cell lineage and for the proliferation of T cell progenitors in the thymus. It has been estimated that activating mutations of NOTCH1 are present in more than 50 percent of patients with T cell ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/105\">",
"     105",
"    </a>",
"    ]. Although the precise mechanisms by which NOTCH1 causes T cell ALL are not yet fully elucidated, studies suggest interaction between NOTCH1 and components of the polycomb repressive complex 2 (PRC2), a highly conserved complex that influences stem cell renewal by epigenetic repression of genes involved in cell fate decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/113\">",
"     113",
"    </a>",
"    ]. Deletion of the NOTCH1 promoter can also result in activation of the Notch1 gene from cryptic initiation sites [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. Spontaneous deletion of the NOTCH1 locus is seen in approximately 75 percent of IKZF1-deficient T cell ALL cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/114\">",
"     114",
"    </a>",
"    ]. Patients with T cell ALL demonstrating a NOTCH1 mutation or a related mutation in FBXW7 may represent a subset with superior event-free and overall survival rates when compared with other patients with T cell ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/116-118\">",
"     116-118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that modulate the expression of genes at the post-transcriptional level, and are involved in cancer, apoptosis, and cell metabolism. They may have particular relevance to T cell ALL. Expression profiles in human T-ALL have identified a small number of abundantly expressed miRNAs that target a set of tumor suppressor genes (IKAROS, PTEN, BIM, NF1, FBXW7, and PHF) and promote T-ALL in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/119\">",
"     119",
"    </a>",
"    ]. Specifically, mir-223 is differentially upregulated in T cell ALL and appears to promote NOTCH1-driven leukemia.",
"   </p>",
"   <p>",
"    Inactivating mutations or deletions in the plant homeodomain finger 6 (PHF6) locus located on the X chromosome are found in 16 percent and 38 percent of primary T cell ALL in children and adults, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/120\">",
"     120",
"    </a>",
"    ]. Loss of PHF6 is associated with aberrant expression of the TLX1 (HOX11) transcription factor oncogene. A role for the deletion of an X-linked locus provides a possible explanation for the increased incidence of this disease in males. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link&amp;anchor=H732703#H732703\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\", section on 'Epidemiologic data'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Up to 15 percent of T cell ALL lack expression of CD1a and CD8 and have weak expression of CD5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/121\">",
"     121",
"    </a>",
"    ]. This subtype, termed &ldquo;early T cell precursor ALL&rdquo;, has a significantly higher rate of treatment failure. Whole genome sequencing of tumor cells from 12 patients with early T cell precursor ALL demonstrated a high frequency of somatic mutations involving the pathways of normal hematopoietic development, RAS signalling, and histone modification, similar to those more frequently involved in acute myeloid leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/122\">",
"     122",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both children and adults with T cell ALL are generally treated with high-risk protocols and often have favorable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/96,123\">",
"     96,123",
"    </a>",
"    ]. At least in children, the type or presence of karyotypic abnormalities does not appear to affect prognosis, as patients with any of the above translocations have an outcome similar to those with normal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/96\">",
"     96",
"    </a>",
"    ]. One study found that T cell ALL with low expression of both ERG and BAALC genes by RT-PCR is associated with significantly lower relapse rates (17 versus 60 percent) and higher four-year overall survival (69 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/25/22938/abstract/124\">",
"     124",
"    </a>",
"    ]. How to apply this information clinically is unclear at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1460654043\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytogenetic analysis and molecular cytogenetic studies, such as fluorescence in situ hybridization (FISH), reveal recurring chromosome abnormalities in approximately 80 percent of B cell acute lymphoblastic leukemia (ALL), including numerical and structural changes, such as translocations, inversions, or deletions. There are substantial differences between children and adults with ALL in the frequencies of recurring abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'B cell acute lymphoblastic leukemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The t(8;14), present in a high proportion of Burkitt cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma,",
"      </span>",
"      occurs in approximately 1 percent of adults with ALL. This translocation is associated with FAB-L3-type leukemia cells (lymphoblasts with deeply basophilic cytoplasm with prominent vacuoles), a high incidence of central nervous system involvement at diagnosis, and a poorer prognosis than any other group of patients classified by chromosomal abnormalities. (See",
"      <a class=\"local\" href=\"#H4\">",
"       '8;14 translocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The t(4;11) is present in up to 60 percent of infants with ALL younger than 12 months, but is rarely observed in adult patients with ALL. This translocation results in a",
"      <span class=\"nowrap\">",
"       MLL/AFF1",
"      </span>",
"      fusion gene, and is associated with a poor prognosis in both adults and children. ALL with the t(4;11) is commonly characterized by high leukocyte counts, an FAB L1 (small cells with scant cytoplasm, condensed chromatin and indistinct nucleoli) or L2 (larger cells with a moderate amount of cytoplasm, dispersed chromatin, and multiple nucleoli) morphology, an immature immunophenotype, B cell lineage, and frequent co-expression of myeloid antigens. (See",
"      <a class=\"local\" href=\"#H5\">",
"       '4;11 translocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The t(9;22) that produces the Philadelphia chromosome is observed in about 2 to 5 percent of children and about 30 percent of adults. This translocation is associated with a poor prognosis. Treatment of patients with the t(9;22) incorporates tyrosine kinase inhibitors that target the",
"      <span class=\"nowrap\">",
"       BCR/ABL1",
"      </span>",
"      protein, which is the fusion product of the Philadelphia chromosome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       '9;22 translocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The t(1;19) occurs in approximately 30 percent of patients with pre-B cell childhood ALL and less commonly in other B lineage ALLs in children and adults. In the past, patients with the t(1;19) typically had early treatment failure. However, this adverse prognosis can be overcome by more intensive chemotherapy such that t(1;19) is now associated with a favorable prognosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       '1;19 translocation in pre-B cell ALL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The t(12;21), resulting in the fusion",
"      <span class=\"nowrap\">",
"       ETV6/RUNX1",
"      </span>",
"      gene, is detectable by FISH or polymerase chain reaction analysis in about 25 percent of children with B-lineage ALL and 3 percent of adults with ALL. Patients with ALL and the t(12;21) generally have a favorable prognosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       '12;21 translocation in precursor B ALL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have hyperdiploidy with more than 50 chromosomes often have a good prognosis. The individual structural abnormalities do not appear to influence outcome in patients with hyperdiploidy except for the t(9;22), which is associated with a poor prognosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hyperdiploidy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 5 to 6 percent of ALL patients, independent of age, have clonal loss of various chromosomes, resulting in a hypodiploid clone with fewer than 46 chromosomes. ALL patients with hypodiploid clones generally have a poor prognosis, especially patients with near-haploid and low-hypodiploid clones. Similarly, deletion of 9p is an unfavorable risk factor associated with a high rate of relapse in precursor-B ALL in children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypodiploidy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       '9p abnormalities in ALL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children with T cell ALL, approximately 60 percent have an abnormal karyotype. These patients have a distinct pattern of recurring karyotypic abnormalities involving both T cell receptor (TCR) and non-TCR gene loci, including activating mutations of NOTCH1 in more than 50 percent. Both children and adults with T cell ALL are generally treated with high-risk protocols and often have favorable outcomes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'T cell acute lymphoblastic leukemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/1\">",
"      Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/2\">",
"      Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Fran&ccedil;ais de Cytog&eacute;n&eacute;tique H&eacute;matologique. Blood 1996; 87:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/3\">",
"      Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/4\">",
"      Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/5\">",
"      Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010; 115:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/6\">",
"      Harrison CJ, Moorman AV, Barber KE, et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 2005; 129:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/7\">",
"      Wetzler M, Dodge RK, Mr&oacute;zek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999; 93:3983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/8\">",
"      Ribeiro RC, Abromowitch M, Raimondi SC, et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987; 70:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/9\">",
"      Russo C, Carroll A, Kohler S, et al. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1991; 77:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/10\">",
"      Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/11\">",
"      Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/12\">",
"      Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/13\">",
"      Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/14\">",
"      Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005; 105:3434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/15\">",
"      Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/16\">",
"      Rubin CM, Le Beau MM, Mick R, et al. Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1991; 9:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/17\">",
"      Pui CH, Frankel LS, Carroll AJ, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991; 77:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/18\">",
"      Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/19\">",
"      Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994; 84:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/20\">",
"      Hilden JM, Frestedt JL, Moore RO, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Blood 1995; 86:3876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/21\">",
"      Bitter MA, Le Beau MM, Rowley JD, et al. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol 1987; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/22\">",
"      Cimino G, Elia L, Rapanotti MC, et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 2000; 95:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/23\">",
"      Cimino G, Elia L, Mancini M, et al. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 2003; 102:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/24\">",
"      Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/25\">",
"      Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009; 23:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/26\">",
"      Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/27\">",
"      Djabali M, Selleri L, Parry P, et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1992; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/28\">",
"      Sun L, Heerema N, Crotty L, et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1999; 96:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/29\">",
"      Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/30\">",
"      Yeoh EJ, Williams K, Patel D, et al. Expression profiling of pediatric acute lymphoblastic leukemia (ALL) blasts at diagnosis accurately predicts both the risk of relapse and of developing therapy-induced acute myeloid leukemia (abstract). Blood 2001; 98:433a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/31\">",
"      Cobaleda C, Guti&eacute;rrez-Cianca N, P&eacute;rez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/32\">",
"      Rambaldi A, Attuati V, Bassan R, et al. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia. Leuk Lymphoma 1996; 21:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/33\">",
"      Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93:3931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/34\">",
"      Campbell LJ, Martinow A, Michael PM, et al. Correlation of cytogenetics, BCR-ABL PCR studies and fluorescence in situ hybridisation (FISH) in adult acute lymphoblastic leukaemia. Aust N Z J Med 1999; 29:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/35\">",
"      Wetzler M, Dodge RK, Mr&oacute;zek K, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 2004; 124:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/36\">",
"      Secker-Walker LM, Craig JM. Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: a review. Leukemia 1993; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/37\">",
"      Anastasi J, Feng J, Dickstein JI, et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia 1996; 10:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/38\">",
"      Hermans A, Heisterkamp N, von Linden M, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/39\">",
"      Fainstein E, Marcelle C, Rosner A, et al. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 1987; 330:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/40\">",
"      Clark SS, McLaughlin J, Timmons M, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988; 239:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/41\">",
"      van Etten RA. Disease progression in a murine model of bcr/abl leukemogenesis. Leuk Lymphoma 1993; 11 Suppl 1:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/42\">",
"      Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/43\">",
"      Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/44\">",
"      Castellanos A, Pintado B, Weruaga E, et al. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood 1997; 90:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/45\">",
"      Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/46\">",
"      Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988; 6:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/47\">",
"      Devaraj PE, Foroni L, Janossy G, et al. Expression of the E2A-PBX1 fusion transcripts in t(1;19)(q23;p13) and der(19)t(1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes. Leukemia 1995; 9:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/48\">",
"      Michael PM, Levin MD, Garson OM. Translocation 1;19--a new cytogenetic abnormality in acute lymphocytic leukemia. Cancer Genet Cytogenet 1984; 12:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/49\">",
"      Pui CH, Raimondi SC, Hancock ML, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol 1994; 12:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/50\">",
"      Crist WM, Carroll AJ, Shuster JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990; 76:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/51\">",
"      Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996; 87:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/52\">",
"      Kamps MP. E2A-Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Curr Top Microbiol Immunol 1997; 220:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/53\">",
"      McWhirter JR, Neuteboom ST, Wancewicz EV, et al. Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci U S A 1999; 96:11464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/54\">",
"      Fu X, McGrath S, Pasillas M, et al. EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1. Oncogene 1999; 18:4920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/55\">",
"      Foa R, Vitale A, Mancini M, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol 2003; 120:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/56\">",
"      Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/57\">",
"      Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86:4263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/58\">",
"      Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997; 15:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/59\">",
"      Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-M&uuml;nster Study Group. Blood 1997; 90:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/60\">",
"      McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88:4252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/61\">",
"      Aguiar RC, Sohal J, van Rhee F, et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996; 95:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/62\">",
"      Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995; 92:4917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/63\">",
"      Lopez RG, Carron C, Oury C, et al. TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999; 274:30132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/64\">",
"      Stegmaier K, Pendse S, Barker GF, et al. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood 1995; 86:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/65\">",
"      Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/66\">",
"      Ritchie KA, Aprikyan AA, Bowen-Pope DF, et al. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice. Leukemia 1999; 13:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/67\">",
"      Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 2002; 99:8242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/68\">",
"      Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood 2003; 102:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/69\">",
"      Ford AM, Palmi C, Bueno C, et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009; 119:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/70\">",
"      Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006; 12:4845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/71\">",
"      Mertens F, Johansson B, Mitelman F. Dichotomy of hyperdiploid acute lymphoblastic leukemia on the basis of the distribution of gained chromosomes. Cancer Genet Cytogenet 1996; 92:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/72\">",
"      Moorman AV, Clark R, Farrell DM, et al. Probes for hidden hyperdiploidy in acute lymphoblastic leukaemia. Genes Chromosomes Cancer 1996; 16:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/73\">",
"      Raimondi SC, Pui CH, Hancock ML, et al. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996; 10:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/74\">",
"      Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004; 125:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/75\">",
"      Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/76\">",
"      Heerema NA, Sather HN, Sensel MG, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 1999; 94:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/77\">",
"      Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/78\">",
"      Coyaud E, Struski S, Prade N, et al. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood 2010; 115:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/79\">",
"      Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/80\">",
"      Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009; 144:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/81\">",
"      Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/82\">",
"      Kuchinskaya E, Heyman M, Nordgren A, et al. Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol. Br J Haematol 2011; 152:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/83\">",
"      Nahi H, H&auml;gglund H, Ahlgren T, et al. An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica 2008; 93:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/84\">",
"      Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. Nat Immunol 2006; 7:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/85\">",
"      Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/86\">",
"      Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008; 112:3847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/87\">",
"      Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/88\">",
"      Roman-Gomez J, Agirre X, Jim&eacute;nez-Velasco A, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009; 27:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/89\">",
"      Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood 2009; 114:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/90\">",
"      Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010; 116:4874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/91\">",
"      Moorman AV, Schwab C, Ensor HM, et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 2012; 30:3100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/92\">",
"      Stock W, Tsai T, Golden C, et al. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood 2000; 95:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/93\">",
"      Hoshino K, Asou N, Okubo T, et al. The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor. Br J Haematol 2002; 117:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/94\">",
"      Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 104:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/95\">",
"      Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/96\">",
"      Heerema NA, Sather HN, Sensel MG, et al. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998; 16:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/97\">",
"      Garand R, Vannier JP, B&eacute;n&eacute; MC, et al. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. The Groupe d'Etude Immunologique des Leuc&eacute;mies. Leukemia 1990; 4:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/98\">",
"      Raimondi SC, Behm FG, Roberson PK, et al. Cytogenetics of childhood T-cell leukemia. Blood 1988; 72:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/99\">",
"      Gardie B, Cayuela JM, Martini S, Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/100\">",
"      McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/101\">",
"      Erikson J, Williams DL, Finan J, et al. Locus of the alpha-chain of the T-cell receptor is split by chromosome translocation in T-cell leukemias. Science 1985; 229:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/102\">",
"      Smith SD, Morgan R, Gemmell R, et al. Clinical and biologic characterization of T-cell neoplasias with rearrangements of chromosome 7 band q34. Blood 1988; 71:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/103\">",
"      Burnett RC, Thirman MJ, Rowley JD, Diaz MO. Molecular analysis of the T-cell acute lymphoblastic leukemia-associated t(1;7)(p34;q34) that fuses LCK and TCRB. Blood 1994; 84:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/104\">",
"      Asnafi V, Radford-Weiss I, Dastugue N, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003; 102:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/105\">",
"      Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/106\">",
"      Strehl S, Nebral K, K&ouml;nig M, et al. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clin Cancer Res 2008; 14:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/107\">",
"      Sulis ML, Williams O, Palomero T, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008; 112:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/108\">",
"      Armstrong F, Brunet de la Grange P, Gerby B, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009; 113:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/109\">",
"      Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 14:3716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/110\">",
"      Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004; 363:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/111\">",
"      De Keersmaecker K, Graux C, Odero MD, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005; 105:4849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/112\">",
"      Della Gatta G, Palomero T, Perez-Garcia A, et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med 2012; 18:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/113\">",
"      Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/114\">",
"      Jeannet R, Mastio J, Macias-Garcia A, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood 2010; 116:5443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/115\">",
"      Ashworth TD, Pear WS, Chiang MY, et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 2010; 116:5455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/116\">",
"      Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009; 113:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/117\">",
"      Mansour MR, Sulis ML, Duke V, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27:4352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/118\">",
"      Ben Abdelali R, Asnafi V, Leguay T, et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood 2011; 118:5099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/119\">",
"      Mavrakis KJ, Van Der Meulen J, Wolfe AL, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011; 43:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/120\">",
"      Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/121\">",
"      Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/122\">",
"      Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/123\">",
"      Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/25/22938/abstract/124\">",
"      Baldus CD, Martus P, Burmeister T, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007; 25:3739.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4484 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22938=[""].join("\n");
var outline_f22_25_22938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1460654043\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      B CELL ACUTE LYMPHOBLASTIC LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - 8;14 translocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - 4;11 translocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H351299836\">",
"      t(11q23) and&nbsp;ALL in infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - 9;22 translocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - 1;19 translocation in pre-B cell ALL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - 12;21 translocation in precursor B ALL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hyperdiploidy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypodiploidy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - 9p abnormalities in ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gene expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cell cycle regulatory genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T CELL ACUTE LYMPHOBLASTIC LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - TCR gene rearrangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Non-TCR loci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1460654043\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=related_link\">",
"      Pathobiology of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_25_22939="Histologic features LIP";
var content_f22_25_22939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic features of lymphoid interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Key histologic features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diffuse interstitial infiltration of involved areas.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Predominantly alveolar septal distribution.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infiltrates compromised mostly of T and/or B lymphocytes, plasma cells, and macrophages.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoid hyperplasia (mucosa-associated lymphoid tissue (MALT) hyperplasia) - frequent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pertinent negative findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of tracking along lymphatic routes (bronchovascular bundles, pleura, and interlobular septa), characteristic of lymphomas.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Organizing pneumonia, inconspicuous or absent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of Dutcher bodies (ie, intranuclear vacuoles containing IgM monoclonal protein seen in Waldenstrom's macroglobulinemia).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of monoclonal light chain staining pattern of plasma cells (polyclonal pattern present).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of extensive pleural involvement or lymph node involvement.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of necrotizing granulomas.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22939=[""].join("\n");
var outline_f22_25_22939=null;
var title_f22_25_22940="Diff dx transient neurologic symptoms";
var content_f22_25_22940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of transient neurologic symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Seizure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transient ischemic attack",
"       </td>",
"       <td class=\"subtitle1\">",
"        Migraine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syncope",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Demography",
"       </td>",
"       <td>",
"        Any age, often younger",
"       </td>",
"       <td>",
"        <p>",
"         Older patients",
"        </p>",
"        <p>",
"         Stroke risk factors present",
"        </p>",
"        Men&gt;women",
"       </td>",
"       <td>",
"        <p>",
"         Younger age",
"        </p>",
"        Women&gt;men",
"       </td>",
"       <td>",
"        <p>",
"         Any age, often younger",
"        </p>",
"        Women&gt;men",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Central nervous system symptoms",
"       </td>",
"       <td>",
"        <p>",
"         Positive symptoms: limb jerking, head turning, loss of consciousness",
"        </p>",
"        Negative symptoms may develop, remain postictally, and persist",
"       </td>",
"       <td>",
"        <p>",
"         Negative symptoms: numbness, visual loss, paralysis, ataxia",
"        </p>",
"        All sensory modalities affected simultaneously",
"       </td>",
"       <td>",
"        First positive symptoms, then negative in same modality: scintillating scotoma and paresthesia most common; second sensory modality is involved after first clears",
"       </td>",
"       <td>",
"        <p>",
"         Light-headed, dim vision, noises distant, decreased alertness",
"        </p>",
"        Transient loss of consciousness",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Timing",
"       </td>",
"       <td>",
"        <p>",
"         20 to 80 seconds",
"        </p>",
"        <p>",
"         Absence, atonic seizures and myoclonic jerks are shorter",
"        </p>",
"        <p>",
"         Postictal depression",
"        </p>",
"        Spells occur during years",
"       </td>",
"       <td>",
"        <p>",
"         Usually minutes, mostly &lt;1 hour",
"        </p>",
"        Spells during days, weeks, months; not usually years",
"       </td>",
"       <td>",
"        <p>",
"         Usually 20 to 30 minutes",
"        </p>",
"        Sporadic attacks during years",
"       </td>",
"       <td>",
"        <p>",
"         Usually a few seconds",
"        </p>",
"        Sporadic attacks during years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated symptoms",
"       </td>",
"       <td>",
"        Tongue biting, incontinence, sore muscles, headache after attack",
"       </td>",
"       <td>",
"        Headaches may occur during time period of TIAs",
"       </td>",
"       <td>",
"        Headache after attack, nausea, vomiting, photophobia, phonophobia",
"       </td>",
"       <td>",
"        Sweating, pallor, nausea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22940=[""].join("\n");
var outline_f22_25_22940=null;
var title_f22_25_22941="Epidemiologic and historic clues encephalitis";
var content_f22_25_22941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiologic and historic clues to the etiology of encephalitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Epidemiologic clues",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Potential etiologies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age (0 to 28 days)",
"       </td>",
"       <td>",
"        <p>",
"         Infectious: CMV, HSV-2 or HSV-1, rubella virus",
"        </p>",
"        Noninfectious: Inborn error of metabolism (eg, organic acidemia, urea cycle disorder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Season:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Summer",
"       </td>",
"       <td class=\"sublist_other\">",
"        Enterovirus, free living amebae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Late summer/fall",
"       </td>",
"       <td class=\"sublist_other\">",
"        Arbovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Winter",
"       </td>",
"       <td class=\"sublist_other\">",
"        Postinfectious encephalitis in countries with low rates of MMR immunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection in horses, birds",
"       </td>",
"       <td>",
"        Arbovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood transfusion or transplant recipient",
"       </td>",
"       <td>",
"        CMV, EBV, HIV, rabies, tick-borne encephalitis, WNV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunodeficiency",
"       </td>",
"       <td>",
"        CMV, enterovirus, HHV6, HSV, VZV, WNV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Historical clues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Vesicular",
"       </td>",
"       <td>",
"        HSV, VZV, enterovirus (hand, foot, and mouth disease), herpes B virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hand, foot, mouth",
"       </td>",
"       <td>",
"        Enterovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Erythematous macules and papules with cephalocaudad spread",
"       </td>",
"       <td>",
"        Measles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Maculopapular",
"       </td>",
"       <td>",
"        WNV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Maculopapular/petechial begins on ankles and wrists",
"       </td>",
"       <td>",
"        Rocky Mountain spotted fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Exposures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mosquitoes",
"       </td>",
"       <td>",
"        Arbovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ticks",
"       </td>",
"       <td>",
"        <em>",
"         Borrelia burgdorferi",
"        </em>",
"        , Powassan virus,",
"        <em>",
"         Rickettsia rickettsii",
"        </em>",
"        , tick-borne encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Animal bite/exposure (dog, bat, cat, birds, livestock, others)",
"       </td>",
"       <td>",
"        Rabies, arboviruses, cat scratch disease, Q fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Blood transfusion or transplant recipient",
"       </td>",
"       <td>",
"        CMV, EBV, HIV, rabies, tick-borne encephalitis, WNV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Recent infectious illness",
"       </td>",
"       <td>",
"        ADEM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Recreational activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Swimming",
"       </td>",
"       <td>",
"        Enteroviruses, free-living amebae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spelunking",
"       </td>",
"       <td>",
"        Rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sexual activity",
"       </td>",
"       <td>",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Travel",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Immunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lack of immunization for specific agent",
"       </td>",
"       <td>",
"        Japanese encephalitis, measles, mumps, rubella, VZV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Recent immunization",
"       </td>",
"       <td>",
"        ADEM",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMV: cytomegalovirus; HSV: herpes simplex virus; MMR: measles, mumps, rubella; EBV: Epstein-Barr virus; HIV: human immunodeficiency virus; WNV: West Nile virus; HHV6: human herpesvirus 6; VZV: varicella zoster virus; ADEM: acute disseminated encephalomyelitis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Willoughby RE, Long SS. Encephalitis, meningoencephalitis, acute disseminated encephalomyelitis, and acute necrotizing encephalopathy. In: Principles and Practice of Pediatric Infectious Diseases, 2nd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. p.310.",
"      </li>",
"      <li>",
"       Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303.",
"      </li>",
"      <li>",
"       Cherry JD, Shields WD, Bronstein DE. Encephalitis and meningoencephalitis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia, 2009. p.504.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22941=[""].join("\n");
var outline_f22_25_22941=null;
var title_f22_25_22942="Altitude work load HF";
var content_f22_25_22942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Maximum work load progressively decreases at higher altitudes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mean reduction in maximal workload, expressed as percentage decreases from baseline, is shown at various simulated altitudes in healthy subjects (filled squares) and heart failure patients with normal baseline functional capacity (filled circles), slightly diminished baseline functional capacity (filled triangles) and severely impaired capacity (open circles). The reduction in work load in those with stable heart failure is in proportion to the limitation in work load seen at sea level, but is greater in those with heart failure who are severely limited.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Agostoni, P, Cattadori, G, Guazzi, M, et al. Effects of Simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. Am J Med 2000; 109:450",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22942=[""].join("\n");
var outline_f22_25_22942=null;
var title_f22_25_22943="Immobile arm in children";
var content_f22_25_22943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F88517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F88517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Immobile arm in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 507px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * More than one attempt or manuever may be needed for successful reduction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_25_22943=[""].join("\n");
var outline_f22_25_22943=null;
